The Promise and Reality of Pharmacogenetics in Psychiatry

Clinics in Laboratory Medicine

Volumn 30, Issue 4, 2010, Pages 931-974

  Zandi, Peter P ^a   Judy, Jennifer T ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Antidepressants; Antipsychotics; Efficacy; Genome wide association study; Mood stabilizers; Pharmacogenetics; Pharmacogenomics; Side effects

Indexed keywords

ANTIDEPRESSANT AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; CITALOPRAM; CLOZAPINE; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; GLYCOGEN SYNTHASE KINASE 3BETA; ILOPERIDONE; LITHIUM; MONOAMINE OXIDASE INHIBITOR; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE; PLACEBO; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID; ZIPRASIDONE;

AGRANULOCYTOSIS; AKATHISIA; BIPOLAR DISORDER; CLINICAL TRIAL; DEPRESSION; DIABETES MELLITUS; DOPAMINERGIC SYSTEM; DRUG EFFICACY; DRUG TOLERABILITY; GENETIC ASSOCIATION; GENETIC VARIABILITY; HAND TREMOR; HUMAN; INSOMNIA; MANIA; MENTAL DISEASE; METABOLIC SYNDROME X; MOOD DISORDER; PARKINSONISM; PATIENT COMPLIANCE; PHARMACODYNAMICS; PHARMACOGENETICS; PHARMACOGENOMICS; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; SCHIZOPHRENIA; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; TARDIVE DYSKINESIA; URINARY FREQUENCY; WEIGHT GAIN;

GENOME-WIDE ASSOCIATION STUDY; HUMANS; MENTAL DISORDERS; PHARMACOGENETICS; PSYCHOPHARMACOLOGY; PSYCHOTROPIC DRUGS;

EID: 77956515350     PISSN: 02722712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cll.2010.07.004     Document Type: Review

References (508)

1. Liu-Seifert H., Adams D.H., Kinon B.J. Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs. BMC Microbiol 2005, 3:21.
2. *D report. Am J Pharmacogenomics 2006, 163:1905-1917.
3. Lieberman J.A., Stroup T.S., McEvoy J.P., et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005, 353:1209-1223.
4. Thase M.E. STEP-BD and bipolar depression: what have we learned?. Curr Psychiatry Rep 2007, 9:497-503.
5. Weinshilboum R., Wang L. Pharmacogenomics: bench to bedside. Nat Rev Drug Discov 2004, 3:739-748.
6. Lieberman J.A. History of the use of antidepressants in primary care. Prim Care Companion J Clin Psychiatry 2003, 5:6-10.
7. Preskorn S.H., Stanga C.Y., Ross R. Selective serotonin reuptake inhibitor. Antidepressants, past, present and future 2004, 242. Springer, New York. S.H. Preskorn, C.Y. Stanga, J.P. Feighner (Eds.).
8. Anderson I.M., Ferrier I.N., Baldwin R.C., et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol 2008, 22:343-396.
9. Crismon M.L., Trivedi M., Pigott T.A., et al. The texas medication algorithm project: report of the texas consensus conference panel on medication treatment of major depressive disorder. J Clin Psychiatry 1999, 60:142-156.
10. Thase M.E., Rush A.J. Treatment-resistant depression. Psychopharmacology: the fourth generation of progress 1995, 1081-1097. Raven Press Ltd, New York. F.E. Bloom, D.J. Kupfer (Eds.).
11. Lin E.H., Von K.M., Katon W., et al. The role of the primary care physician in patients' adherence to antidepressant therapy. Med Care 1995, 33:67-74.
12. Chen S., Chou W.H., Blouin R.A., et al. The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry. Clin Pharmacol Ther 1996, 60:522-534.
13. Smeraldi E., Zanardi R., Benedetti F., et al. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry 1998, 3:508-511.
14. Kim D.K., Lim S.W., Lee S., et al. Serotonin transporter gene polymorphism and antidepressant response. Neuroreport 2000, 11:215-219.
15. Pollock B.G., Ferrell R.E., Mulsant B.H., et al. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 2000, 23:587-590.
16. Zanardi R., Benedetti F., Di B.D., et al. Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. J Clin Psychopharmacol 2000, 20:105-107.
17. Zill P., Baghai T.C., Zwanzger P., et al. Evidence for an association between a G-protein beta3-gene variant with depression and response to antidepressant treatment. Neuroreport 2000, 11:1893-1897.
18. Minov C., Baghai T.C., Schule C., et al. Serotonin-2A-receptor and -transporter polymorphisms: lack of association in patients with major depression. Neurosci Lett 2001, 303:119-122.
19. Serretti A., Zanardi R., Cusin C., et al. Tryptophan hydroxylase gene associated with paroxetine antidepressant activity. Eur Neuropsychopharmacol 2001, 11:375-380.
20. Serretti A., Zanardi R., Rossini D., et al. Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity. Mol Psychiatry 2001, 6:586-592.
21. Zanardi R., Serretti A., Rossini D., et al. Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression. Biol Psychiatry 2001, 50:323-330.
22. Allgulander C., Nilsson B. A prospective study of 86 new patients with social anxiety disorder. Acta Psychiatr Scand 2001, 103:447-452.
23. Baghai T.C., Schule C., Zwanzger P., et al. Possible influence of the insertion/deletion polymorphism in the angiotensin I-converting enzyme gene on therapeutic outcome in affective disorders. Mol Psychiatry 2001, 6:258-259.
24. Wang J.H., Liu Z.Q., Wang W., et al. Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19. Clin Pharmacol Ther 2001, 70:42-47.
25. Wu W.H., Huo S.J., Cheng C.Y., et al. Association study of the 5-HT(6) receptor polymorphism (C267T) and symptomatology and antidepressant response in major depressive disorders. Neuropsychobiology 2001, 44:172-175.
26. Cusin C., Serretti A., Zanardi R., et al. Influence of monoamine oxidase a and serotonin receptor 2A polymorphisms in SSRI antidepressant activity. Int J Neuropsychopharmacol 2002, 5:27-35.
27. Yoshida K., Ito K., Sato K., et al. Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 2002, 26:383-386.
28. Yu Y.W., Tsai S.J., Chen T.J., et al. Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders. Mol Psychiatry 2002, 7:1115-1119.
29. Hong C.J., Wang Y.C., Tsai S.J. Association study of angiotensin I-converting enzyme polymorphism and symptomatology and antidepressant response in major depressive disorders. J Neural Transm 2002, 109:1209-1214.
30. Ito K., Yoshida K., Sato K., et al. A variable number of tandem repeats in the serotonin transporter gene does not affect the antidepressant response to fluvoxamine. Psychiatry Res 2002, 111:235-239.
31. Muller D.J., Schulze T.G., Macciardi F., et al. Moclobemide response in depressed patients: association study with a functional polymorphism in the monoamine oxidase a promoter. Pharmacopsychiatry 2002, 35:157-158.
32. Sato K., Yoshida K., Takahashi H., et al. Association between -1438G/A promoter polymorphism in the 5-HT(2A) receptor gene and fluvoxamine response in Japanese patients with major depressive disorder. Neuropsychobiology 2002, 46:136-140.
33. Yoshida K., Naito S., Takahashi H., et al. Monoamine oxidase: a gene polymorphism, tryptophan hydroxylase gene polymorphism and antidepressant response to fluvoxamine in Japanese patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2002, 26:1279-1283.
34. Rausch J.L., Johnson M.E., Fei Y.J., et al. Initial conditions of serotonin transporter kinetics and genotype: influence on SSRI treatment trial outcome. Biol Psychiatry 2002, 51:723-732.
35. Takahashi H., Yoshida K., Ito K., et al. No association between the serotonergic polymorphisms and incidence of nausea induced by fluvoxamine treatment. Eur Neuropsychopharmacol 2002, 12:477-481.
36. Serretti A., Lorenzi C., Cusin C., et al. SSRIs antidepressant activity is influenced by G beta 3 variants. Eur Neuropsychopharmacol 2003, 13:117-122.
37. Arias B., Catalan R., Gasto C., et al. 5-HTTLPR polymorphism of the serotonin transporter gene predicts non-remission in major depression patients treated with citalopram in a 12-weeks follow up study. J Clin Psychopharmacol 2003, 23:563-567.
38. Joyce P.R., Mulder R.T., Luty S.E., et al. Age-dependent antidepressant pharmacogenomics: polymorphisms of the serotonin transporter and G protein beta3 subunit as predictors of response to fluoxetine and nortriptyline. Int J Neuropsychopharmacol 2003, 6:339-346.
39. Murphy G.M., Kremer C., Rodrigues H.E., et al. Pharmacogenetics of antidepressant medication intolerance. Am J Psychiatry 2003, 160:1830-1835.
40. Gerstenberg G., Aoshima T., Fukasawa T., et al. Relationship between clinical effects of fluvoxamine and the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients. Psychopharmacology (Berl) 2003, 167:443-448.
41. Perlis R.H., Mischoulon D., Smoller J.W., et al. Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment. Biol Psychiatry 2003, 54:879-883.
42. Tsai S.J., Cheng C.Y., Yu Y.W., et al. Association study of a brain-derived neurotrophic-factor genetic polymorphism and major depressive disorders, symptomatology, and antidepressant response. Am J Med Genet B NeuroPsychiatr Genet 2003, 123B:19-22.
43. Yoshida K., Naito S., Takahashi H., et al. Monoamine oxidase a gene polymorphism, 5-HT 2A receptor gene polymorphism and incidence of nausea induced by fluvoxamine. Neuropsychobiology 2003, 48:10-13.
44. Durham L.K., Webb S.M., Milos P.M., et al. The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder. Psychopharmacology (Berl) 2004, 174:525-529.
45. Lee M.S., Lee H.Y., Lee H.J., et al. Serotonin transporter promoter gene polymorphism and long-term outcome of antidepressant treatment. Psychiatr Genet 2004, 14:111-115.
46. Murphy G.M., Hollander S.B., Rodrigues H.E., et al. Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Arch Gen Psychiatry 2004, 61:1163-1169.
47. Peters E.J., Slager S.L., McGrath P.J., et al. Investigation of serotonin-related genes in antidepressant response. Mol Psychiatry 2004, 9:879-889.
48. Rau T., Wohlleben G., Wuttke H., et al. CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants: a pilot study. Clin Pharmacol Ther 2004, 75:386-393.
49. Serretti A., Cusin C., Rossini D., et al. Further evidence of a combined effect of SERTPR and TPH on SSRIs response in mood disorders. Am J Med Genet B NeuroPsychiatr Genet 2004, 129B:36-40.
50. Serretti A., Artioli P., Lorenzi C., et al. The C(-1019)G polymorphism of the 5-HT1A gene promoter and antidepressant response in mood disorders: preliminary findings. Int J Neuropsychopharmacol 2004, 7:453-460.
51. Yoshida K., Takahashi H., Higuchi H., et al. Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms. Am J Psychiatry 2004, 161:1575-1580.
52. Baghai T.C., Schule C., Zill P., et al. The angiotensin I converting enzyme insertion/deletion polymorphism influences therapeutic outcome in major depressed women, but not in men. Neurosci Lett 2004, 363:38-42.
53. Binder E.B., Salyakina D., Lichtner P., et al. Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat Genet 2004, 36:1319-1325.
54. Grasmader K., Verwohlt P.L., Rietschel M., et al. Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting. Eur J Clin Pharmacol 2004, 60:329-336.
55. Kawanishi C., Lundgren S., Agren H., et al. Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse: a pilot study. Eur J Clin Pharmacol 2004, 59:803-807.
56. Lee H.J., Cha J.H., Ham B.J., et al. Association between a G-protein beta 3 subunit gene polymorphism and the symptomatology and treatment responses of major depressive disorders. Pharmacogenomics J 2004, 4:29-33.
57. Lemonde S., Du L., Bakish D., et al. Association of the C(-1019)G 5-HT1A functional promoter polymorphism with antidepressant response. Int J Neuropsychopharmacol 2004, 7:501-506.
58. Licinio J., O'Kirwan F., Irizarry K., et al. Association of a corticotropin-releasing hormone receptor 1 haplotype and antidepressant treatment response in Mexican-Americans. Mol Psychiatry 2004, 9:1075-1082.
59. Roberts R.L., Mulder R.T., Joyce P.R., et al. No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline. Hum Psychopharmacol 2004, 19:17-23.
60. Suzuki Y., Sawamura K., Someya T. The effects of a 5-hydroxytryptamine 1A receptor gene polymorphism on the clinical response to fluvoxamine in depressed patients. Pharmacogenomics J 2004, 4:283-286.
61. Zill P., Baghai T.C., Engel R., et al. The dysbindin gene in major depression: an association study. Am J Med Genet B NeuroPsychiatr Genet 2004, 129B:55-58.
62. Arias B., Catalan R., Gasto C., et al. Evidence for a combined genetic effect of the 5-HT(1A) receptor and serotonin transporter genes in the clinical outcome of major depressive patients treated with citalopram. J Psychopharmacol 2005, 19:166-172.
63. Ham B.J., Lee M.S., Lee H.J., et al. No association between the tryptophan hydroxylase gene polymorphism and major depressive disorders and antidepressant response in a Korean population. Psychiatr Genet 2005, 15:299-301.
64. Szegedi A., Rujescu D., Tadic A., et al. The catechol-O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression. Pharmacogenomics J 2005, 5:49-53.
65. Choi M.J., Kang R.H., Ham B.J., et al. Serotonin receptor 2A gene polymorphism (-1438A/G) and short-term treatment response to citalopram. Neuropsychobiology 2005, 52:155-162.
66. Garriock H.A., Allen J.J., Delgado P., et al. Lack of association of TPH2 exon XI polymorphisms with major depression and treatment resistance. Mol Psychiatry 2005, 10:976-977.
67. Kato M., Ikenaga Y., Wakeno M., et al. Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism. Int Clin Psychopharmacol 2005, 20:151-156.
68. Kraft J.B., Slager S.L., McGrath P.J., et al. Sequence analysis of the serotonin transporter and associations with antidepressant response. Biol Psychiatry 2005, 58:374-381.
69. Lee S.H., Lee K.J., Lee H.J., et al. Association between the 5-HT6 receptor C267T polymorphism and response to antidepressant treatment in major depressive disorder. Psychiatry Clin Neurosci 2005, 59:140-145.
70. Yu Y.W., Tsai S.J., Hong C.J., et al. Association study of a monoamine oxidase a gene promoter polymorphism with major depressive disorder and antidepressant response. Neuropsychopharmacology 2005, 30:1719-1723.
71. McMahon F.J., Buervenich S., Charney D., et al. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet 2006, 78:804-814.
72. Arias B., Serretti A., Lorenzi C., et al. Analysis of COMT gene (Val 158 Met polymorphism) in the clinical response to SSRIs in depressive patients of European origin. J Atten Disord 2006, 90:251-256.
73. Hong C.J., Chen T.J., Yu Y.W., et al. Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder. Pharmacogenomics J 2006, 6:27-33.
74. Kato M., Fukuda T., Wakeno M., et al. Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients. Neuropsychobiology 2006, 53:186-195.
75. Shams M.E., Arneth B., Hiemke C., et al. CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. J Clin Pharm Ther 2006, 31:493-502.
76. Smeraldi E., Serretti A., Artioli P., et al. Serotonin transporter gene-linked polymorphic region: possible pharmacogenetic implications of rare variants. Psychiatr Genet 2006, 16:153-158.
77. Yu Y.W., Tsai S.J., Liou Y.J., et al. Association study of two serotonin 1A receptor gene polymorphisms and fluoxetine treatment response in Chinese major depressive disorders. Eur Neuropsychopharmacol 2006, 16:498-503.
78. Bishop J.R., Moline J., Ellingrod V.L., et al. Serotonin 2A -1438 G/A and G-protein Beta3 subunit C825T polymorphisms in patients with depression and SSRI-associated sexual side-effects. Neuropsychopharmacology 2006, 31:2281-2288.
79. Choi M.J., Kang R.H., Lim S.W., et al. Brain-derived neurotrophic factor gene polymorphism (Val66Met) and citalopram response in major depressive disorder. Brain Res 2006, 1118:176-182.
80. Ng C.H., Easteal S., Tan S., et al. Serotonin transporter polymorphisms and clinical response to sertraline across ethnicities. Prog Neuropsychopharmacol Biol Psychiatry 2006, 30:953-957.
81. Popp J., Leucht S., Heres S., et al. Serotonin transporter polymorphisms and side effects in antidepressant therapy: a pilot study. Pharmacogenomics 2006, 7:159-166.
82. Sugai T., Suzuki Y., Sawamura K., et al. The effect of 5-hydroxytryptamine 3A and 3B receptor genes on nausea induced by paroxetine. Pharmacogenomics J 2006, 6:351-356.
83. Suzuki Y., Sawamura K., Someya T. Polymorphisms in the 5-hydroxytryptamine 2A receptor and cytochrome P4502D6 genes synergistically predict fluvoxamine-induced side effects in japanese depressed patients. Neuropsychopharmacology 2006, 31:825-831.
84. Kim H., Lim S.W., Kim S., et al. Monoamine transporter gene polymorphisms and antidepressant response in koreans with late-life depression. JAMA 2006, 296:1609-1618.
85. *D study. Arch Gen Psychiatry 2007, 64:689-697.
86. Ham B.J., Lee B.C., Paik J.W., et al. Association between the tryptophan hydroxylase-1 gene A218C polymorphism and citalopram antidepressant response in a Korean population. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:104-107.
87. Hu X.Z., Rush A.J., Charney D., et al. Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. Arch Gen Psychiatry 2007, 64:783-792.
88. Kirchheiner J., Nickchen K., Sasse J., et al. A 40-basepair VNTR polymorphism in the dopamine transporter (DAT1) gene and the rapid response to antidepressant treatment. Pharmacogenomics J 2007, 7:48-55.
89. Levin G.M., Bowles T.M., Ehret M.J., et al. Assessment of human serotonin 1A receptor polymorphisms and SSRI responsiveness. Mol Diagn Ther 2007, 11:155-160.
90. Kraft J.B., Peters E.J., Slager S.L., et al. Analysis of association between the serotonin transporter and antidepressant response in a large clinical sample. Biol Psychiatry 2007, 61:734-742.
91. Kang R.H., Wong M.L., Choi M.J., et al. Association study of the serotonin transporter promoter polymorphism and mirtazapine antidepressant response in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:1317-1321.
92. Kang R.H., Hahn S.W., Choi M.J., et al. Relationship between G-protein beta-3 subunit C825T polymorphism and mirtazapine responses in Korean patients with major depression. Neuropsychobiology 2007, 56:1-5.
93. Kato M., Wakeno M., Okugawa G., et al. No association of TPH1 218A/C polymorphism with treatment response and intolerance to SSRIs in Japanese patients with major depression. Neuropsychobiology 2007, 56:167-171.
94. Kronenberg S., Apter A., Brent D., et al. Serotonin transporter polymorphism (5-HTTLPR) and citalopram effectiveness and side effects in children with depression and/or anxiety disorders. J Child Adolesc Psychopharmacol 2007, 17:741-750.
95. Laje G., Paddock S., Manji H., et al. Genetic markers of suicidal ideation emerging during citalopram treatment of major depression. Am J Psychiatry 2007, 164:1530-1538.
96. Liu Z., Zhu F., Wang G., et al. Association study of corticotropin-releasing hormone receptor1 gene polymorphisms and antidepressant response in major depressive disorders. Neurosci Lett 2007, 414:155-158.
97. *D cohort. Am J Psychiatry 2007, 164:1181-1188.
98. Pae C.U., Serretti A., Mandelli L., et al. Dysbindin associated with selective serotonin reuptake inhibitor antidepressant efficacy. Pharmacogenet Genomics 2007, 17:69-75.
99. Papiol S., Arias B., Gasto C., et al. Genetic variability at HPA axis in major depression and clinical response to antidepressant treatment. J Affect Disord 2007, 104:83-90.
100. Smits K., Smits L., Peeters F., et al. Serotonin transporter polymorphisms and the occurrence of adverse events during treatment with selective serotonin reuptake inhibitors. Int Clin Psychopharmacol 2007, 22:137-143.
101. Tadic A., Muller M.J., Rujescu D., et al. The MAOA T941G polymorphism and short-term treatment response to mirtazapine and paroxetine in major depression. Am J Med Genet B Neuropsychiatr Genet 2007, 144:325-331.
102. Tsai S.J., Hong C.J., Chen T.J., et al. Lack of supporting evidence for a genetic association of the FKBP5 polymorphism and response to antidepressant treatment. Am J Med Genet B Neuropsychiatr Genet 2007, 144:1097-1098.
103. Wilkie M.J., Smith D., Reid I.C., et al. A splice site polymorphism in the G-protein beta subunit influences antidepressant efficacy in depression. Pharmacogenet Genomics 2007, 17:207-215.
104. Yoshida K., Higuchi H., Kamata M., et al. The G196A polymorphism of the brain-derived neurotrophic factor gene and the antidepressant effect of milnacipran and fluvoxamine. J Psychopharmacol 2007, 21:650-656.
105. Benedetti F., Barbini B., Bernasconi A., et al. Lithium overcomes the influence of 5-HTTLPR gene polymorphism on antidepressant response to sleep deprivation. J Clin Psychopharmacol 2008, 28:249-251.
106. Lotrich F.E., Pollock B.G., Kirshner M., et al. Serotonin transporter genotype interacts with paroxetine plasma levels to influence depression treatment response in geriatric patients. J Psychiatry Neurosci 2008, 33:123-130.
107. Uhr M., Tontsch A., Namendorf C., et al. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron 2008, 57:203-209.
108. *D sample. PLoS One 2008, 3:e1872.
109. Baune B.T., Hohoff C., Roehrs T., et al. Serotonin receptor 1A-1019C/G variant: impact on antidepressant pharmacoresponse in melancholic depression?. Neurosci Lett 2008, 436:111-115.
110. Bozina N., Peles A.M., Sagud M., et al. Association study of paroxetine therapeutic response with SERT gene polymorphisms in patients with major depressive disorder. World J Biol Psychiatry 2008, 9:190-197.
111. Gex-Fabry M., Eap C.B., Oneda B., et al. CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response. Ther Drug Monit 2008, 30:474-482.
112. Gratacos M., Soria V., Urretavizcaya M., et al. A brain-derived neurotrophic factor (BDNF) haplotype is associated with antidepressant treatment outcome in mood disorders. Pharmacogenomics J 2008, 8:101-112.
113. Kato M., Fukuda T., Serretti A., et al. ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:398-404.
114. Kato M., Wakeno M., Okugawa G., et al. Antidepressant response and intolerance to SSRI is not influenced by G-protein beta3 subunit gene C825T polymorphism in Japanese major depressive patients. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:1041-1044.
115. *D). Cohort Biol Psychiatry 2008, 63:1103-1110.
116. Mihaljevic P.A., Bozina N., Sagud M., et al. MDR1 gene polymorphism: therapeutic response to paroxetine among patients with major depression. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:1439-1444.
117. Smits K.M., Smits L.J., Peeters F.P., et al. The influence of 5-HTTLPR and STin2 polymorphisms in the serotonin transporter gene on treatment effect of selective serotonin reuptake inhibitors in depressive patients. Psychiatr Genet 2008, 18:184-190.
118. Tanaka M., Kobayashi D., Murakami Y., et al. Genetic polymorphisms in the 5-hydroxytryptamine type 3B receptor gene and paroxetine-induced nausea. Int J Neuropsychopharmacol 2008, 11:261-267.
119. Yoshida K., Higuchi H., Takahashi H., et al. Influence of the tyrosine hydroxylase val81met polymorphism and catechol-O-methyltransferase val158met polymorphism on the antidepressant effect of milnacipran. Hum Psychopharmacol 2008, 23:121-128.
120. Bishop J.R., Ellingrod V.L., Akroush M., et al. The association of serotonin transporter genotypes and selective serotonin reuptake inhibitor (SSRI)-associated sexual side effects: possible relationship to oral contraceptives. Hum Psychopharmacol 2009, 24:207-215.
121. Wilkie M.J., Smith G., Day R.K., et al. Polymorphisms in the SLC6A4 and HTR2A genes influence treatment outcome following antidepressant therapy. Pharmacogenomics J 2009, 9:61-70.
122. Arias B., Serretti A., Mandelli L., et al. Dysbindin gene (DTNBP1) in major depression: association with clinical response to selective serotonin reuptake inhibitors. Pharmacogenet Genomics 2009, 19:121-128.
123. Cabanero M., Laje G., Detera-Wadleigh S., et al. Association study of phosphodiesterase genes in the sequenced treatment alternatives to relieve depression sample. Pharmacogenet Genomics 2009, 19:235-238.
124. Domschke K., Lawford B., Laje G., et al. Brain-derived neurotrophic factor (BDNF) gene: no major impact on antidepressant treatment response. Int J Neuropsychopharmacol 2010, 13(1):93-101.
125. Kang R., Chang H., Wong M., et al. Brain-derived neurotrophic factor gene polymorphisms and mirtazapine responses in Koreans with major depression. J Psychopharmacol 2009, [Epub ahead of print].
126. Kato M., Fukuda T., Wakeno M., et al. Effect of 5-HT1A gene polymorphisms on antidepressant response in major depressive disorder. Am J Med Genet B Neuropsychiatr Genet 2009, 150:115-123.
127. Mrazek D.A., Rush A.J., Biernacka J.M., et al. SLC6A4 variation and citalopram response. Am J Med Genet B Neuropsychiatr Genet 2009, 150:341-351.
128. Perlis R.H., Fijal B., Adams D.H., et al. Variation in catechol-O-methyltransferase is associated with duloxetine response in a clinical trial for major depressive disorder. Biol Psychiatry 2009, 65:785-791.
129. Perlis R.H., Laje G., Smoller J.W., et al. Genetic and clinical predictors of sexual dysfunction in citalopram-treated depressed patients. Neuropsychopharmacology 2009, 34:1819-1828.
130. Secher A., Bukh J., Bock C., et al. Antidepressive-drug-induced bodyweight gain is associated with polymorphisms in genes coding for COMT and TPH1. Int Clin Psychopharmacol 2009, 24:199-203.
131. Laje G., Allen A.S., Akula N., et al. Genome-wide association study of suicidal ideation emerging during citalopram treatment of depressed outpatients. Pharmacogenet Genomics 2009, 19:666-674.
132. Garriock H.A., Kraft J.B., Shyn S.I., et al. A genome-wide association study of citalopram response in major depressive disorder. Biol Psychiatry 2010, 67:133-138.
133. Ising M., Lucae S., Binder E.B., et al. A genome-wide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. Arch Gen Psychiatry 2009, 66:966-975.
134. Brosen K. Some aspects of genetic polymorphism in the biotransformation of antidepressants. Therapiewoche 2004, 59:5-12.
135. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 2005, 5:6-13.
136. Bertilsson L., Dahl M.L., Dalen P., et al. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol 2002, 53:111-122.
137. Madan A., Graham R.A., Carroll K.M., et al. Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab Dispos 2003, 31:421-431.
138. de L.J., Armstrong S.C., Cozza K.L. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psychosomatics 2006, 47:75-85.
139. Nebert D.W., Dieter M.Z. The evolution of drug metabolism. Pharmacology 2000, 61:124-135.
140. de L.J. AmpliChip CYP450 test: personalized medicine has arrived in psychiatry. Expert Rev Mol Diagn 2006, 6:277-286.
141. Thakur M., Grossman I., McCrory D.C., et al. Review of evidence for genetic testing for CYP450 polymorphisms in management of patients with nonpsychotic depression with selective serotonin reuptake inhibitors. Genet Med 2007, 9:826-835.
142. Heils A., Teufel A., Petri S., et al. Allelic variation of human serotonin transporter gene expression. J Neurochem 1996, 66:2621-2624.
143. Hu X.Z., Lipsky R.H., Zhu G., et al. Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. Am J Hum Genet 2006, 78:815-826.
144. Hranilovic D., Stefulj J., Schwab S., et al. Serotonin transporter promoter and intron 2 polymorphisms: relationship between allelic variants and gene expression. Biol Psychiatry 2004, 55:1090-1094.
145. Serretti A., Kato M., De R.D., et al. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry 2007, 12:247-257.
146. Kato M., Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry 2010, 15(5):473-500.
147. Walther D.J., Peter J.U., Bashammakh S., et al. Synthesis of serotonin by a second tryptophan hydroxylase isoform. Science 2003, 299:76.
148. Nakamura K., Sugawara Y., Sawabe K., et al. Late developmental stage-specific role of tryptophan hydroxylase 1 in brain serotonin levels. J Neurosci 2006, 26:530-534.
149. Binder D.K., Scharfman H.E. Brain-derived neurotrophic factor. Growth Factors 2004, 22:123-131.
150. Shorter E. The history of lithium therapy. Bipolar Disord 2009, 11(Suppl 2):4-9.
151. Grof P., Muller-Oerlinghausen B. A critical appraisal of lithium's efficacy and effectiveness: the last 60 years. Bipolar Disord 2009, 11(Suppl 2):10-19.
152. Young A.H., Hammond J.M. Lithium in mood disorders: increasing evidence base, declining use?. Br J Psychiatry 2007, 191:474-476.
153. Coryell W. Maintenance treatment in bipolar disorder: a reassessment of lithium as the first choice. Bipolar Disord 2009, 11(Suppl 2):77-83.
154. Cavazzoni P., Alda M., Turecki G., et al. Lithium-responsive affective disorders: no association with the tyrosine hydroxylase gene. Psychiatry Res 1996, 64:91-96.
155. Turecki G., Alda M., Grof P., et al. No association between chromosome-18 markers and lithium-responsive affective disorders. Psychiatry Res 1996, 63:17-23.
156. Steen V.M., Gulbrandsen A.K., Eiken H.G., et al. Lack of genetic variation in the coding region of the myo-inositol monophosphatase gene in lithium-treated patients with manic depressive illness. Pharmacogenetics 1996, 6:113-116.
157. Turecki G., Grof P., Cavazzoni P., et al. Evidence for a role of phospholipase C-gamma1 in the pathogenesis of bipolar disorder. Mol Psychiatry 1998, 3:534-538.
158. Alda M., Grof P., Grof E. MN blood groups and bipolar disorder: evidence of genotypic association and Hardy-Weinberg disequilibrium. Biol Psychiatry 1998, 44:361-363.
159. Steen V.M., Lovlie R., Osher Y., et al. The polymorphic inositol polyphosphate 1-phosphatase gene as a candidate for pharmacogenetic prediction of lithium-responsive manic-depressive illness. Pharmacogenetics 1998, 8:259-268.
160. Serretti A., Lilli R., Lorenzi C., et al. Dopamine receptor D3 gene and response to lithium prophylaxis in mood disorders. Int J Neuropsychopharmacol 1998, 1:125-129.
161. Turecki G., Grof P., Cavazzoni P., et al. association and linkage studies with lithium responsive bipolar disorder. Psychiatr Genet 1999, 9:13-16.
162. Serretti A., Lilli R., Lorenzi C., et al. Dopamine receptor D2 and D4 genes, GABA(A) alpha-1 subunit genes and response to lithium prophylaxis in mood disorders. Psychiatry Res 1999, 87:7-19.
163. Serretti A., Lilli R., Lorenzi C., et al. Tryptophan hydroxylase gene and response to lithium prophylaxis in mood disorders. J Psychiatr Res 1999, 33:371-377.
164. Duffy A., Turecki G., Grof P., et al. Association and linkage studies of candidate genes involved in GABAergic neurotransmission in lithium-responsive bipolar disorder. J Psychiatry Neurosci 2000, 25:353-358.
165. Alda M., Turecki G., Grof P., et al. Association and linkage studies of CRH and PENK genes in bipolar disorder: a collaborative IGSLI study. Am J Med Genet 2000, 96:178-181.
166. Serretti A., Lorenzi C., Lilli R., et al. Serotonin receptor 2A, 2C, 1A genes and response to lithium prophylaxis in mood disorders. J Psychiatr Res 2000, 34:89-98.
167. Ftouhi-Paquin N., Alda M., Grof P., et al. Identification of three polymorphisms in the translated region of PLC-gamma1 and their investigation in lithium responsive bipolar disorder. Am J Med Genet 2001, 105:301-305.
168. Serretti A., Lilli R., Mandelli L., et al. Serotonin transporter gene associated with lithium prophylaxis in mood disorders. Pharmacogenomics J 2001, 1:71-77.
169. Lovlie R., Berle J.O., Stordal E., et al. The phospholipase C-gamma1 gene (PLCG1) and lithium-responsive bipolar disorder: re-examination of an intronic dinucleotide repeat polymorphism. Psychiatr Genet 2001, 11:41-43.
170. Serretti A., Lorenzi C., Lilli R., et al. Pharmacogenetics of lithium prophylaxis in mood disorders: analysis of COMT, MAO-A, and Gbeta3 variants. Am J Med Genet 2002, 114:370-379.
171. Washizuka S., Ikeda A., Kato N., et al. Possible relationship between mitochondrial DNA polymorphisms and lithium response in bipolar disorder. Int J Neuropsychopharmacol 2003, 6:421-424.
172. Dmitrzak-Weglarz M., Rybakowski J.K., Suwalska A., et al. Association studies of 5-HT2A and 5-HT2C serotonin receptor gene polymorphisms with prophylactic lithium response in bipolar patients. Pharmacol Rep 2005, 57:761-765.
173. Rybakowski J.K., Suwalska A., Skibinska M., et al. Prophylactic lithium response and polymorphism of the brain-derived neurotrophic factor gene. Pharmacopsychiatry 2005, 38:166-170.
174. Rybakowski J.K., Suwalska A., Czerski P.M., et al. Prophylactic effect of lithium in bipolar affective illness may be related to serotonin transporter genotype. Pharmacol Rep 2005, 57:124-127.
175. Benedetti F., Serretti A., Pontiggia A., et al. Long-term response to lithium salts in bipolar illness is influenced by the glycogen synthase kinase 3-beta -50 T/C SNP. Neurosci Lett 2005, 376:51-55.
176. Szczepankiewicz A., Rybakowski J.K., Suwalska A., et al. Association study of the glycogen synthase kinase-3beta gene polymorphism with prophylactic lithium response in bipolar patients. World J Biol Psychiatry 2006, 7:158-161.
177. Masui T., Hashimoto R., Kusumi I., et al. Lithium response and Val66Met polymorphism of the brain-derived neurotrophic factor gene in Japanese patients with bipolar disorder. Psychiatr Genet 2006, 16:49-50.
178. Masui T., Hashimoto R., Kusumi I., et al. A possible association between the -116C/G single nucleotide polymorphism of the XBP1 gene and lithium prophylaxis in bipolar disorder. Int J Neuropsychopharmacol 2006, 9:83-88.
179. Michelon L., Meira-Lima I., Cordeiro Q., et al. Association study of the INPP1, 5HTT, BDNF, AP-2beta and GSK-3beta GENE variants and restrospectively scored response to lithium prophylaxis in bipolar disorder. Neurosci Lett 2006, 403:288-293.
180. Mamdani F., Sequeira A., Alda M., et al. No association between the PREP gene and lithium responsive bipolar disorder. BMC Psychiatry 2007, 7:9.
181. Bremer T., Diamond C., McKinney R., et al. The pharmacogenetics of lithium response depends upon clinical co-morbidity. Mol Diagn Ther 2007, 11:161-170.
182. Rybakowski J.K., Suwalska A., Skibinska M., et al. Response to lithium prophylaxis: interaction between serotonin transporter and BDNF genes. Am J Med Genet B Neuropsychiatr Genet 2007, 144B:820-823.
183. Mamdani F., Alda M., Grof P., et al. Lithium response and genetic variation in the CREB family of genes. Am J Med Genet B Neuropsychiatr Genet 2008, 147B:500-504.
184. Dmitrzak-Weglarz M., Rybakowski J.K., Suwalska A., et al. Association studies of the BDNF and the NTRK2 gene polymorphisms with prophylactic lithium response in bipolar patients. Pharmacogenomics 2008, 9:1595-1603.
185. Masui T., Hashimoto R., Kusumi I., et al. A possible association between missense polymorphism of the breakpoint cluster region gene and lithium prophylaxis in bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:204-208.
186. Kim B., Kim C.Y., Lee M.J., et al. Preliminary evidence on the association between XBP1-116C/G polymorphism and response to prophylactic treatment with valproate in bipolar disorders. Psychiatry Res 2009, 168:209-212.
187. Szczepankiewicz A., Skibinska M., Suwalska A., et al. No association of three GRIN2B polymorphisms with lithium response in bipolar patients. Pharmacol Rep 2009, 61:448-452.
188. Szczepankiewicz A., Skibinska M., Suwalska A., et al. The association study of three FYN polymorphisms with prophylactic lithium response in bipolar patients. Hum Psychopharmacol 2009, 24:287-291.
189. Rybakowski J.K., Dmitrzak-Weglarz M., Suwalska A., et al. Dopamine D1 receptor gene polymorphism is associated with prophylactic lithium response in bipolar disorder. Pharmacopsychiatry 2009, 42:20-22.
190. Perlis R.H., Smoller J.W., Ferreira M.A., et al. A genome-wide association study of response to lithium for prevention of recurrence in bipolar disorder. Am J Psychiatry 2009, 166:718-725.
191. Berridge M.J., Downes C.P., Hanley M.R. Neural and developmental actions of lithium: a unifying hypothesis. Cell 1989, 59:411-419.
192. Harwood A.J. Lithium and bipolar mood disorder: the inositol-depletion hypothesis revisited. Mol Psychiatry 2005, 10:117-126.
193. Klein P.S., Melton D.A. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci U S A 1996, 93:8455-8459.
194. Williams R.S., Harwood A.J. Lithium therapy and signal transduction. Trends Pharmacol Sci 2000, 21:61-64.
195. Jope R.S., Bijur G.N. Mood stabilizers, glycogen synthase kinase-3beta and cell survival. Mol Psychiatry 2002, 7(Suppl 1):S35-S45.
196. Chen G., Huang L.D., Jiang Y.M., et al. The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. J Neurochem 1999, 72:1327-1330.
197. Bajjalieh S.M., Peterson K., Linial M., et al. Brain contains two forms of synaptic vesicle protein 2. Proc Natl Acad Sci U S A 1993, 90:2150-2154.
198. Seelan R.S., Khalyfa A., Lakshmanan J., et al. Deciphering the lithium transcriptome: microarray profiling of lithium-modulated gene expression in human neuronal cells. Neuroscience 2008, 151:1184-1197.
199. Ben-Zur T., Feige E., Motro B., et al. The mammalian Odz gene family: homologs of a Drosophila pair-rule gene with expression implying distinct yet overlapping developmental roles. Dev Biol 2000, 217:107-120.
200. Shen W.W. A history of antipsychotic drug development. Compr Psychiatry 1999, 40:407-414.
201. Kane J., Honigfeld G., Singer J., et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988, 45:789-796.
202. Leucht S., Corves C., Arbter D., et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009, 373:31-41.
203. Sharif Z. Side effects as influencers of treatment outcome. J Clin Psychiatry 2008, 69(Suppl 3):38-43.
204. Arranz M., Collier D., Sodhi M., et al. Association between clozapine response and allelic variation in 5-HT2A receptor gene. Lancet 1995, 346:281-282.
205. Arranz M.J., Dawson E., Shaikh S., et al. Cytochrome P4502D6 genotype does not determine response to clozapine. Br J Clin Psychol 1995, 39:417-420.
206. Masellis M., Paterson A.D., Badri F., et al. Genetic variation of 5-HT2A receptor and response to clozapine. Lancet 1995, 346:1108.
207. Nothen M.M., Rietschel M., Erdmann J., et al. Genetic variation of the 5-HT2A receptor and response to clozapine. Lancet 1995, 346:908-909.
208. Sodhi M.S., Arranz M.J., Curtis D., et al. Association between clozapine response and allelic variation in the 5-HT2C receptor gene. Neuroreport 1995, 7:169-172.
209. Malhotra A.K., Goldman D., Ozaki N., et al. Lack of association between polymorphisms in the 5-HT2A receptor gene and the antipsychotic response to clozapine. Am J Psychiatry 1996, 153:1092-1094.
210. Arranz M.J., Collier D.A., Munro J., et al. Analysis of a structural polymorphism in the 5-HT2A receptor and clinical response to clozapine. Neurosci Lett 1996, 217:177-178.
211. Gaitonde E.J., Morris A., Sivagnanasundaram S., et al. Assessment of association of D3 dopamine receptor MscI polymorphism with schizophrenia: analysis of symptom ratings, family history, age at onset, and movement disorders. Am J Med Genet 1996, 67:455-458.
212. Jonsson E., Nothen M.M., Bunzel R., et al. 5HT 2a receptor T102C polymorphism and schizophrenia. Lancet 1996, 347:1831.
213. Rietschel M., Naber D., Oberlander H., et al. Efficacy and side-effects of clozapine: testing for association with allelic variation in the dopamine D4 receptor gene. Neuropsychopharmacology 1996, 15:491-496.
214. Rietschel M., Naber D., Fimmers R., et al. Efficacy and side-effects of clozapine not associated with variation in the 5-HT2C receptor. Neuroreport 1997, 8:1999-2003.
215. Steen V.M., Lovlie R., MacEwan T., et al. Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients. Mol Psychiatry 1997, 2:139-145.
216. Turbay D., Lieberman J., Alper C.A., et al. Tumor necrosis factor constellation polymorphism and clozapine-induced agranulocytosis in two different ethnic groups. Blood 1997, 89:4167-4174.
217. *0201. Int J Neuropsychopharmacol 1998, 1:41-44.
218. Arranz M.J., Munro J., Owen M.J., et al. Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to clozapine. Mol Psychiatry 1998, 3:61-66.
219. Hwu H.G., Hong C.J., Lee Y.L., et al. Dopamine D4 receptor gene polymorphisms and neuroleptic response in schizophrenia. Biol Psychiatry 1998, 44:483-487.
220. Masellis M., Basile V., Meltzer H.Y., et al. Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients. Neuropsychopharmacology 1998, 19:123-132.
221. Valevski A., Klein T., Gazit E., et al. HLA-B38 and clozapine-induced agranulocytosis in Israeli Jewish schizophrenic patients. Eur J Immunol 1998, 25:11-13.
222. Aitchison K.J., Munro J., Wright P., et al. Failure to respond to treatment with typical antipsychotics is not associated with CYP2D6 ultrarapid hydroxylation. Br J Clin Pharmacol 1999, 48:388-394.
223. Basile V.S., Masellis M., Badri F., et al. Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia. Neuropsychopharmacology 1999, 21:17-27.
224. Cohen B.M., Ennulat D.J., Centorrino F., et al. Polymorphisms of the dopamine D4 receptor and response to antipsychotic drugs. Psychopharmacology (Berl) 1999, 141:6-10.
225. Joober R., Benkelfat C., Brisebois K., et al. T102C polymorphism in the 5HT2A gene and schizophrenia: relation to phenotype and drug response variability. J Psychiatry Neurosci 1999, 24:141-146.
226. Lin C.H., Tsai S.J., Yu Y.W., et al. No evidence for association of serotonin-2A receptor variant (102T/C) with schizophrenia or clozapine response in a Chinese population. Neuroreport 1999, 10:57-60.
227. Scharfetter J., Chaudhry H.R., Hornik K., et al. Dopamine D3 receptor gene polymorphism and response to clozapine in schizophrenic Pakastani patients. Eur Neuropsychopharmacol 1999, 10:17-20.
228. Segman R., Neeman T., Heresco-Levy U., et al. Genotypic association between the dopamine D3 receptor and tardive dyskinesia in chronic schizophrenia. Mol Psychiatry 1999, 4:247-253.
229. Yu Y.W., Tsai S.J., Lin C.H., et al. Serotonin-6 receptor variant (C267T) and clinical response to clozapine. Neuroreport 1999, 10:1231-1233.
230. Arranz M.J., Munro J., Birkett J., et al. Pharmacogenetic prediction of clozapine response. Lancet 2000, 355:1615-1616.
231. Arranz M.J., Bolonna A.A., Munro J., et al. The serotonin transporter and clozapine response. Mol Psychiatry 2000, 5:124-125.
232. Basile V.S., Ozdemir V., Masellis M., et al. A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia. Mol Psychiatry 2000, 5:410-417.
233. Birkett J.T., Arranz M.J., Munro J., et al. Association analysis of the 5-HT5A gene in depression, psychosis and antipsychotic response. Neuroreport 2000, 11:2017-2020.
234. Bolonna A.A., Arranz M.J., Munro J., et al. No influence of adrenergic receptor polymorphisms on schizophrenia and antipsychotic response. Neurosci Lett 2000, 280:65-68.
235. Chong S.A., Tan E.C., Tan C.H., et al. Tardive dyskinesia is not associated with the serotonin gene polymorphism (5-HTTLPR) in Chinese. Am J Med Genet 2000, 96:712-715.
236. Dettling M., Sachse C., Muller-Oerlinghausen B., et al. Clozapine-induced agranulocytosis and hereditary polymorphisms of clozapine metabolizing enzymes: no association with myeloperoxidase and cytochrome P4502D6. Pharmacopsychiatry 2000, 33:218-220.
237. Eichhammer P., Albus M., Borrmann-Hassenbach M., et al. Association of dopamine D3-receptor gene variants with neuroleptic induced akathisia in schizophrenic patients: a generalization of Steen's study on DRD3 and tardive dyskinesia. Am J Med Genet 2000, 96:187-191.
238. Joober R., Toulouse A., Benkelfat C., et al. DRD3 and DAT1 genes in schizophrenia: an association study. J Psychiatr Res 2000, 34:285-291.
239. Joober R., Benkelfat C., Lal S., et al. Association between the methylenetetrahydrofolate reductase 677C->T missense mutation and schizophrenia. Mol Psychiatry 2000, 5:323-326.
240. Kaiser R., Konneker M., Henneken M., et al. Dopamine D4 receptor 48-bp repeat polymorphism: no association with response to antipsychotic treatment, but association with catatonic schizophrenia. Mol Psychiatry 2000, 5:418-424.
241. Krebs M.O., Guillin O., Bourdell M.C., et al. Brain derived neurotrophic factor (BDNF) gene variants association with age at onset and therapeutic response in schizophrenia. Mol Psychiatry 2000, 5:558-562.
242. Lovlie R., Daly A.K., Blennerhassett R., et al. Homozygosity for the Gly-9 variant of the dopamine D3 receptor and risk for tardive dyskinesia in schizophrenic patients. Int J Neuropsychopharmacol 2000, 3:61-65.
243. Mihara K., Suzuki A., Kondo T., et al. No relationship between Taq1 a polymorphism of dopamine D(2) receptor gene and extrapyramidal adverse effects of selective dopamine D(2) antagonists, bromperidol, and nemonapride in schizophrenia: a preliminary study. Am J Med Genet 2000, 96:422-424.
244. Rietschel M., Krauss H., Muller D.J., et al. Dopamine D3 receptor variant and tardive dyskinesia. Eur Arch Psychiatry Clin Neurosci 2000, 250:31-35.
245. Scordo M.G., Spina E., Romeo P., et al. CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients. Eur J Clin Pharmacol 2000, 56:679-683.
246. Segman R.H., Heresco-Levy U., Finkel B., et al. Association between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia: additive contribution of 5-HT2Cser and DRD3gly alleles to susceptibility. Psychopharmacology (Berl) 2000, 152:408-413.
247. Tsai S.J., Hong C.J., Yu Y.W., et al. Association study of a functional serotonin transporter gene polymorphism with schizophrenia, psychopathology and clozapine response. Schizophr Res 2000, 44:177-181.
248. Basile V.S., Ozdemir V., Masellis M., et al. Lack of association between serotonin-2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophrenia. Mol Psychiatry 2001, 6:230-234.
249. Basile V.S., Masellis M., McIntyre R.S., et al. Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle. J Clin Psychiatry 2001, 62(Suppl 23):45-66.
250. Dahmen N., Muller M.J., Germeyer S., et al. Genetic polymorphisms of the dopamine D2 and D3 receptor and neuroleptic drug effects in schizophrenic patients. Schizophr Res 2001, 49:223-225.
251. Dettling M., Cascorbi I., Roots I., et al. Genetic determinants of clozapine-induced agranulocytosis: recent results of HLA subtyping in a non-Jewish caucasian sample. Arch Gen Psychiatry 2001, 58:93-94.
252. Garcia-Barcelo M.M., Lam L.C., Ungvari G.S., et al. Dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients. J Neural Transm 2001, 108:671-677.
253. Hong C.J., Lin C.H., Yu Y.W., et al. Genetic variants of the serotonin system and weight change during clozapine treatment. Pharmacogenetics 2001, 11:265-268.
254. Hong C.J., Yu Y.W., Lin C.H., et al. Association analysis for NMDA receptor subunit 2B (GRIN2B) genetic variants and psychopathology and clozapine response in schizophrenia. Psychiatr Genet 2001, 11:219-222.
255. Hori H., Ohmori O., Shinkai T., et al. Association between three functional polymorphisms of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia. Am J Med Genet 2001, 105:774-778.
256. Kaiser R., Tremblay P.B., Schmider J., et al. Serotonin transporter polymorphisms: no association with response to antipsychotic treatment, but associations with the schizoparanoid and residual subtypes of schizophrenia. Mol Psychiatry 2001, 6:179-185.
257. Liao D.L., Yeh Y.C., Chen H.M., et al. Association between the Ser9Gly polymorphism of the dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients. Neuropsychobiology 2001, 44:95-98.
258. Masellis M., Basile V.S., Meltzer H.Y., et al. Lack of association between the T->C 267 serotonin 5-HT6 receptor gene (HTR6) polymorphism and prediction of response to clozapine in schizophrenia. Schizophr Res 2001, 47:49-58.
259. Mihara K., Kondo T., Suzuki A., et al. No relationship between-141C Ins/Del polymorphism in the promoter region of dopamine D2 receptor and extrapyramidal adverse effects of selective dopamine D2 antagonists in schizophrenic patients: a preliminary study. Psychiatry Res 2001, 101:33-38.
260. *10 allele in Korean schizophrenic patients. Eur J Clin Pharmacol 2001, 57:671-675.
261. Schafer M., Rujescu D., Giegling I., et al. Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D(2) receptor gene. Am J Psychiatry 2001, 158:802-804.
262. Schulze T.G., Schumacher J., Muller D.J., et al. Lack of association between a functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene and tardive dyskinesia in schizophrenia. Am J Med Genet 2001, 105:498-501.
263. Segman R.H., Heresco-Levy U., Finkel B., et al. Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia. Mol Psychiatry 2001, 6:225-229.
264. Suzuki A., Kondo T., Otani K., et al. Association of the TaqI A polymorphism of the dopamine D(2) receptor gene with predisposition to neuroleptic malignant syndrome. Am J Psychiatry 2001, 158:1714-1716.
265. Suzuki A., Kondo T., Mihara K., et al. The -141C Ins/Del polymorphism in the dopamine D2 receptor gene promoter region is associated with anxiolytic and antidepressive effects during treatment with dopamine antagonists in schizophrenic patients. Pharmacogenetics 2001, 11:545-550.
266. Tan E.C., Chong S.A., Mahendran R., et al. Susceptibility to neuroleptic-induced tardive dyskinesia and the T102C polymorphism in the serotonin type 2A receptor. Biol Psychiatry 2001, 50:144-147.
267. Tsai S.J., Wang Y.C., Yu Younger W.Y., et al. Association analysis of polymorphism in the promoter region of the alpha2a-adrenoceptor gene with schizophrenia and clozapine response. Schizophr Res 2001, 49:53-58.
268. Yu Y.W., Tsai S.J., Yang K.H., et al. Evidence for an association between polymorphism in the serotonin-2A receptor variant (102T/C) and increment of N100 amplitude in schizophrenics treated with clozapine. Neuropsychobiology 2001, 43:79-82.
269. Basile V.S., Masellis M., De L.V., et al. 759C/T genetic variation of 5HT(2C) receptor and clozapine-induced weight gain. Lancet 2002, 360:1790-1791.
270. Brockmoller J., Kirchheiner J., Schmider J., et al. The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin Pharmacol Ther 2002, 72:438-452.
271. Ellingrod V.L., Miller D., Schultz S.K., et al. CYP2D6 polymorphisms and atypical antipsychotic weight gain. Psychiatr Genet 2002, 12:55-58.
272. Gutierrez B., Arranz M.J., Huezo-Diaz P., et al. Novel mutations in 5-HT3A and 5-HT3B receptor genes not associated with clozapine response. Schizophr Res 2002, 58:93-97.
273. Himei A., Koh J., Sakai J., et al. The influence on the schizophrenic symptoms by the DRD2Ser/Cys311 and -141C Ins/Del polymorphisms. Psychiatry Clin Neurosci 2002, 56:97-102.
274. Kaiser R., Tremblay P.B., Klufmoller F., et al. Relationship between adverse effects of antipsychotic treatment and dopamine D(2) receptor polymorphisms in patients with schizophrenia. Mol Psychiatry 2002, 7:695-705.
275. Lane H.Y., Chang Y.C., Chiu C.C., et al. Association of risperidone treatment response with a polymorphism in the 5-HT(2A) receptor gene. Am J Psychiatry 2002, 159:1593-1595.
276. Lerer B., Segman R.H., Fangerau H., et al. Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism. Neuropsychopharmacology 2002, 27:105-119.
277. Mancama D., Arranz M.J., Munro J., et al. Investigation of promoter variants of the histamine 1 and 2 receptors in schizophrenia and clozapine response. Neurosci Lett 2002, 333:207-211.
278. Mihara K., Kondo T., Higuchi H., et al. Tardive dystonia and genetic polymorphisms of cytochrome P4502D6 and dopamine D2 and D3 receptors: a preliminary finding. Am J Med Genet 2002, 114:693-695.
279. Ohmori O., Shinkai T., Hori H., et al. Genetic association analysis of 5-HT(6) receptor gene polymorphism (267C/T) with tardive dyskinesia. Psychiatry Res 2002, 110:97-102.
280. Reynolds G.P., Zhang Z.J., Zhang X.B. Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. Lancet 2002, 359:2086-2087.
281. Schillevoort I., de B.A., van der Weide J., et al. Antipsychotic-induced extrapyramidal syndromes and cytochrome P450 2D6 genotype: a case-control study. Pharmacogenetics 2002, 12:235-240.
282. Segman R.H., Heresco-Levy U., Yakir A., et al. Interactive effect of cytochrome P450 17alpha-hydroxylase and dopamine D3 receptor gene polymorphisms on abnormal involuntary movements in chronic schizophrenia. Biol Psychiatry 2002, 51:261-263.
283. Segman R.H., Lerer B. Age and the relationship of dopamine D3, serotonin 2C and serotonin 2A receptor genes to abnormal involuntary movements in chronic schizophrenia. Mol Psychiatry 2002, 7:137-139.
284. Staddon S., Arranz M.J., Mancama D., et al. Clinical applications of pharmacogenetics in psychiatry. Psychopharmacology (Berl) 2002, 162:18-23.
285. Tsai S.J., Hong C.J., Yu Y.W., et al. 759C/T genetic variation of 5HT(2C) receptor and clozapine-induced weight gain. Lancet 2002, 360:1790.
286. Woo S.I., Kim J.W., Rha E., et al. Association of the Ser9Gly polymorphism in the dopamine D3 receptor gene with tardive dyskinesia in Korean schizophrenics. Psychiatry Clin Neurosci 2002, 56:469-474.
287. Zhang Z., Zhang X., Hou G., et al. The increased activity of plasma manganese superoxide dismutase in tardive dyskinesia is unrelated to the Ala-9Val polymorphism. J Psychiatr Res 2002, 36:317-324.
288. Zhang Z.J., Zhang X.B., Sha W.W., et al. Association of a polymorphism in the promoter region of the serotonin 5-HT2C receptor gene with tardive dyskinesia in patients with schizophrenia. Mol Psychiatry 2002, 7:670-671.
289. Chong S.A., Tan E.C., Tan C.H., et al. Polymorphisms of dopamine receptors and tardive dyskinesia among Chinese patients with schizophrenia. Am J Med Genet B Neuropsychiatr Genet. 2003, 116B:51-54.
290. Herken H., Erdal M.E., Boke O., et al. Tardive dyskinesia is not associated with the polymorphisms of 5-HT2A receptor gene, serotonin transporter gene and catechol-o-methyltransferase gene. Eur Psychiatry 2003, 18:77-81.
291. Hong C.J., Yu Y.W., Lin C.H., et al. An association study of a brain-derived neurotrophic factor Val66Met polymorphism and clozapine response of schizophrenic patients. Neurosci Lett 2003, 349:206-208.
292. Inada T., Senoo H., Iijima Y., et al. Cytochrome P450 II D6 gene polymorphisms and the neuroleptic-induced extrapyramidal symptoms in Japanese schizophrenic patients. Psychiatr Genet 2003, 13:163-168.
293. Kishida I., Kawanishi C., Furuno T., et al. Lack of association in Japanese patients between neuroleptic malignant syndrome and the TaqI A polymorphism of the dopamine D2 receptor gene. Psychiatr Genet 2003, 13:55-57.
294. Lohmann P.L., Bagli M., Krauss H., et al. CYP2D6 polymorphism and tardive dyskinesia in schizophrenic patients. Pharmacopsychiatry 2003, 36:73-78.
295. Mihara K., Kondo T., Suzuki A., et al. Relationship between functional dopamine D2 and D3 receptors gene polymorphisms and neuroleptic malignant syndrome. Am J Med Genet B Neuropsychiatr Genet 2003, 117B:57-60.
296. Ostrousky O., Meged S., Loewenthal R., et al. NQO2 gene is associated with clozapine-induced agranulocytosis. Tissue Antigens 2003, 62:483-491.
297. Reynolds G.P., Zhang Z., Zhang X. Polymorphism of the promoter region of the serotonin 5-HT(2C) receptor gene and clozapine-induced weight gain. Am J Psychiatry 2003, 160:677-679.
298. Tsai S.J., Hong C.J., Yu Y.W., et al. No association of tumor necrosis factor alpha gene polymorphisms with schizophrenia or response to clozapine. Schizophr Res 2003, 65:27-32.
299. Zalsman G., Frisch A., Lev-Ran S., et al. DRD4 exon III polymorphism and response to risperidone in Israeli adolescents with schizophrenia: a pilot pharmacogenetic study. Eur Neuropsychopharmacol 2003, 13:183-185.
300. Zhang Z.J., Yao Z.J., Zhang X.B., et al. No association of antipsychotic agent-induced weight gain with a DA receptor gene polymorphism and therapeutic response. Acta Pharmacol Sin 2003, 24:235-240.
301. Anttila S., Illi A., Kampman O., et al. Interaction between NOTCH4 and catechol-O-methyltransferase genotypes in schizophrenia patients with poor response to typical neuroleptics. Pharmacogenetics 2004, 14:303-307.
302. Bertolino A., Caforio G., Blasi G., et al. Interaction of COMT (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia. Am J Psychiatry 2004, 161:1798-1805.
303. Huezo-Diaz P., Arranz M.J., Munro J., et al. An association study of the neurotensin receptor gene with schizophrenia and clozapine response. Schizophr Res 2004, 66:193-195.
304. Kampman O., Anttila S., Illi A., et al. Neuregulin genotype and medication response in Finnish patients with schizophrenia. Neuroreport 2004, 15:2517-2520.
305. Kishida I., Kawanishi C., Furuno T., et al. Association in Japanese patients between neuroleptic malignant syndrome and functional polymorphisms of the dopamine D(2) receptor gene. Mol Psychiatry 2004, 9:293-298.
306. Lane H.Y., Lee C.C., Chang Y.C., et al. Effects of dopamine D2 receptor Ser311Cys polymorphism and clinical factors on risperidone efficacy for positive and negative symptoms and social function. Int J Neuropsychopharmacol 2004, 7:461-470.
307. Lane H.Y., Lin C.C., Huang C.H., et al. Risperidone response and 5-HT6 receptor gene variance: genetic association analysis with adjustment for nongenetic confounders. Schizophr Res 2004, 67:63-70.
308. Lattuada E., Cavallaro R., Serretti A., et al. Tardive dyskinesia and DRD2, DRD3, DRD4, 5-HT2A variants in schizophrenia: an association study with repeated assessment. Int J Neuropsychopharmacol 2004, 7:489-493.
309. Liou Y.J., Liao D.L., Chen J.Y., et al. Association analysis of the dopamine D3 receptor gene ser9gly and brain-derived neurotrophic factor gene val66met polymorphisms with antipsychotic-induced persistent tardive dyskinesia and clinical expression in Chinese schizophrenic patients. Neuromolecular Med 2004, 5:243-251.
310. *10 C188T polymorphism is associated with antipsychotic-induced persistent tardive dyskinesia in Chinese schizophrenic patients. Neuropsychobiology 2004, 49:167-173.
311. Matsumoto C., Ohmori O., Shinkai T., et al. Genetic association analysis of functional polymorphisms in the cytochrome P450 1A2 (CYP1A2) gene with tardive dyskinesia in Japanese patients with schizophrenia. Psychiatr Genet 2004, 14:209-213.
312. Matsumoto C., Shinkai T., Hori H., et al. Polymorphisms of dopamine degradation enzyme (COMT and MAO) genes and tardive dyskinesia in patients with schizophrenia. Psychiatry Res 2004, 127:1-7.
313. Mosyagin I., Dettling M., Roots I., et al. Impact of myeloperoxidase and NADPH-oxidase polymorphisms in drug-induced agranulocytosis. J Clin Psychopharmacol 2004, 24:613-617.
314. Pae C.U., Yu H.S., Kim J.J., et al. Quinone oxidoreductase (NQO1) gene polymorphism (609C/T) may be associated with tardive dyskinesia, but not with the development of schizophrenia. Int J Neuropsychopharmacol 2004, 7:495-500.
315. Shinkai T., Ohmori O., Matsumoto C., et al. Genetic association analysis of neuronal nitric oxide synthase gene polymorphism with tardive dyskinesia. Neuromolecular Med 2004, 5:163-170.
316. Szekeres G., Keri S., Juhasz A., et al. Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2004, 124B:1-5.
317. Tsai S.J., Yu Y.W., Lin C.H., et al. Association study of adrenergic beta3 receptor (Trp64Arg) and G-protein beta3 subunit gene (C825T) polymorphisms and weight change during clozapine treatment. Neuropsychobiology 2004, 50:37-40.
318. Wang Y.C., Liou Y.J., Liao D.L., et al. Association analysis of a neural nitric oxide synthase gene polymorphism and antipsychotics-induced tardive dyskinesia in Chinese schizophrenic patients. J Neural Transm 2004, 111:623-629.
319. Weickert T.W., Goldberg T.E., Mishara A., et al. Catechol-O-methyltransferase val108/158met genotype predicts working memory response to antipsychotic medications. Biol Psychiatry 2004, 56:677-682.
320. Templeman L.A., Reynolds G.P., Arranz B., et al. Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in caucasian subjects with a first-episode psychosis. Pharmacogenet Genomics 2005, 15:195-200.
321. Theisen F.M., Gebhardt S., Haberhausen M., et al. Clozapine-induced weight gain: a study in monozygotic twins and same-sex sib pairs. Psychiatr Genet 2005, 15:285-289.
322. Anttila S., Illi A., Kampman O., et al. Lack of association between two polymorphisms of brain-derived neurotrophic factor and response to typical neuroleptics. J Neural Transm 2005, 112:885-890.
323. Bishop J.R., Ellingrod V.L., Moline J., et al. Association between the polymorphic GRM3 gene and negative symptom improvement during olanzapine treatment. Schizophr Res 2005, 77:253-260.
324. de L.J., Susce M.T., Pan R.M., et al. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry 2005, 66:15-27.
325. de L.J., Susce M.T., Pan R.M., et al. Polymorphic variations in GSTM1, GSTT1, PgP, CYP2D6, CYP3A5, and dopamine D2 and D3 receptors and their association with tardive dyskinesia in severe mental illness. J Clin Psychopharmacol 2005, 25:448-456.
326. De L.V., Vincent J.B., Muller D.J., et al. Identification of a naturally occurring 21 bp deletion in alpha 2c noradrenergic receptor gene and cognitive correlates to antipsychotic treatment. Pharm Res 2005, 51:381-384.
327. Deshpande S.N., Varma P.G., Semwal P., et al. Serotonin receptor gene polymorphisms and their association with tardive dyskinesia among schizophrenia patients from North India. Psychiatr Genet 2005, 15:157-158.
328. Ellingrod V.L., Perry P.J., Ringold J.C., et al. Weight gain associated with the -759C/T polymorphism of the 5HT2C receptor and olanzapine. Am J Med Genet B Neuropsychiatr Genet 2005, 134B:76-78.
329. Hamdani N., Bonniere M., Ades J., et al. Negative symptoms of schizophrenia could explain discrepant data on the association between the 5-HT2A receptor gene and response to antipsychotics. Neurosci Lett 2005, 377:69-74.
330. Hwang R., Shinkai T., De L.V., et al. Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory/intolerant populations. Psychopharmacology (Berl) 2005, 181:179-187.
331. Kakihara S., Yoshimura R., Shinkai K., et al. Prediction of response to risperidone treatment with respect to plasma concencentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6. Int Clin Psychopharmacol 2005, 20:71-78.
332. Kim J.Y., Jung I.K., Han C., et al. Antipsychotics and dopamine transporter gene polymorphisms in delirium patients. Psychiatry Clin Neurosci 2005, 59:183-188.
333. Lai I.C., Wang Y.C., Lin C.C., et al. Negative association between catechol-O-methyltransferase (COMT) gene Val158Met polymorphism and persistent tardive dyskinesia in schizophrenia. J Neural Transm 2005, 112:1107-1113.
334. Lane H.Y., Hsu S.K., Liu Y.C., et al. Dopamine D3 receptor Ser9Gly polymorphism and risperidone response. J Clin Psychopharmacol 2005, 25:6-11.
335. Liou Y.J., Wang Y.C., Lin C.C., et al. Association analysis of NAD(P)Hratioquinone oxidoreductase (NQO1) Pro187Ser genetic polymorphism and tardive dyskinesia in patients with schizophrenia in Taiwan. Int J Neuropsychopharmacol 2005, 8:483-486.
336. Miller D.D., Ellingrod V.L., Holman T.L., et al. Clozapine-induced weight gain associated with the 5HT2C receptor -759C/T polymorphism. Am J Med Genet B Neuropsychiatr Genet 2005, 133B:97-100.
337. Muller D.J., Klempan T.A., De L.V., et al. The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia. Neurosci Lett 2005, 379:81-89.
338. Muller D.J., De L.V., Sicard T., et al. Suggestive association between the C825T polymorphism of the G-protein beta3 subunit gene (GNB3) and clinical improvement with antipsychotics in schizophrenia. Eur Neuropsychopharmacol 2005, 15:525-531.
339. Reynolds G.P., Yao Z., Zhang X., et al. Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response. Eur Neurol 2005, 15:143-151.
340. Shinkai T., De L.V., Hwang R., et al. Association study between a functional glutathione S-transferase (GSTP1) gene polymorphism (Ile105Val) and tardive dyskinesia. Neurosci Lett 2005, 388:116-120.
341. Tiwari A.K., Deshpande S.N., Rao A.R., et al. Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: I. Association of CYP1A2 gene polymorphism. Pharmacogenomics J 2005, 5:60-69.
342. Tiwari A.K., Deshpande S.N., Rao A.R., et al. Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: III. Lack of association of CYP3A4 and CYP2D6 gene polymorphisms. Schizophr Res 2005, 75:21-26.
343. Wang Y.C., Bai Y.M., Chen J.Y., et al. Polymorphism of the adrenergic receptor alpha 2a -1291C>G genetic variation and clozapine-induced weight gain. J Neural Transm 2005, 112:1463-1468.
344. Wang Y.C., Bai Y.M., Chen J.Y., et al. C825T polymorphism in the human G protein beta3 subunit gene is associated with long-term clozapine treatment-induced body weight change in the Chinese population. Pharmacogenet Genomics 2005, 15:743-748.
345. Wu S., Xing Q., Gao R., et al. Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients. Neurosci Lett 2005, 376:1-4.
346. Zhao A.L., Zhao J.P., Zhang Y.H., et al. Dopamine D4 receptor gene exon III polymorphism and interindividual variation in response to clozapine. Int J Neurosci 2005, 115:1539-1547.
347. Bishop J.R., Ellingrod V.L., Moline J., et al. Pilot study of the G-protein beta3 subunit gene (C825T) polymorphism and clinical response to olanzapine or olanzapine-related weight gain in persons with schizophrenia. Med Sci Monit 2006, 12:BR47-BR50.
348. Fu Y., Fan C.H., Deng H.H., et al. Association of CYP2D6 and CYP1A2 gene polymorphism with tardive dyskinesia in Chinese schizophrenic patients. Acta Pharmacol Sin 2006, 27:328-332.
349. Hwang R., Shinkai T., Deluca V., et al. Dopamine D2 receptor gene variants and quantitative measures of positive and negative symptom response following clozapine treatment. Eur Neuropsychopharmacol 2006, 16:248-259.
350. Kampman O., Illi A., Hanninen K., et al. RGS4 genotype is not associated with antipsychotic medication response in schizophrenia. J Neural Transm 2006, 113:1563-1568.
351. Lencz T., Robinson D.G., Xu K., et al. DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients. Am J Psychiatry 2006, 163:529-531.
352. Liou Y.J., Lai I.C., Liao D.L., et al. The human dopamine receptor D2 (DRD2) gene is associated with tardive dyskinesia in patients with schizophrenia. Schizophr Res 2006, 86:323-325.
353. Liou Y.J., Lai I.C., Lin M.W., et al. Haplotype analysis of endothelial nitric oxide synthase (NOS3) genetic variants and tardive dyskinesia in patients with schizophrenia. Pharmacogenet Genomics 2006, 16:151-157.
354. Mata I., Crespo-Facorro B., Perez-Iglesias R., et al. Association between the interleukin-1 receptor antagonist gene and negative symptom improvement during antipsychotic treatment. Am J Med Genet B Neuropsychiatr Genet 2006, 141B:939-943.
355. Park Y.M., Chung Y.C., Lee S.H., et al. Weight gain associated with the alpha2a-adrenergic receptor -1,291 C/G polymorphism and olanzapine treatment. Am J Med Genet B Neuropsychiatr Genet 2006, 141B:394-397.
356. Reynolds G.P., Arranz B., Templeman L.A., et al. Effect of 5-HT1A receptor gene polymorphism on negative and depressive symptom response to antipsychotic treatment of drug-naive psychotic patients. Am J Psychiatry 2006, 163:1826-1829.
357. Richardson M.A., Chao H.M., Read L.L., et al. Investigation of the phenylalanine hydroxylase gene and tardive dyskinesia. Am J Med Genet B Neuropsychiatr Genet 2006, 141B:195-197.
358. Shinkai T., Muller D.J., De L.V., et al. Genetic association analysis of the glutathione peroxidase (GPX1) gene polymorphism (Pro197Leu) with tardive dyskinesia. Psychiatry Res 2006, 141:123-128.
359. Srivastava V., Varma P.G., Prasad S., et al. Genetic susceptibility to tardive dyskinesia among schizophrenia subjects: IV. Role of dopaminergic pathway gene polymorphisms. Pharmacogenet Genomics 2006, 16:111-117.
360. Takao T., Tachikawa H., Kawanishi Y., et al. Association of treatment-resistant schizophrenia with the G2677A/T and C3435T polymorphisms in the ATP-binding cassette subfamily B member 1 gene. Psychiatr Genet 2006, 16:47-48.
361. Yasui-Furukori N., Saito M., Nakagami T., et al. Association between multidrug resistance 1 (MDR1) gene polymorphisms and therapeutic response to bromperidol in schizophrenic patients: a preliminary study. Prog Neuropsychopharmacol Biol Psychiatry 2006, 30:286-291.
362. Zai G., Muller D.J., Volavka J., et al. Family and case-control association study of the tumor necrosis factor-alpha (TNF-alpha) gene with schizophrenia and response to antipsychotic medication. Psychopharmacology (Berl) 2006, 188:171-182.
363. Strous R.D., Greenbaum L., Kanyas K., et al. Association of the dopamine receptor interacting protein gene, NEF3, with early response to antipsychotic medication. Int J Neuropsychopharmacol 2007, 10:321-333.
364. Woodward N.D., Jayathilake K., Meltzer H.Y. COMT val108/158met genotype, cognitive function, and cognitive improvement with clozapine in schizophrenia. Schizophr Res 2007, 90:86-96.
365. Anttila S., Kampman O., Illi A., et al. Association between 5-HT2A, TPH1 and GNB3 genotypes and response to typical neuroleptics: a serotonergic approach. BMC Psychiatry 2007, 7:22.
366. Bertolino A., Caforio G., Blasi G., et al. COMT Val158Met polymorphism predicts negative symptoms response to treatment with olanzapine in schizophrenia. Schizophr Res 2007, 95:253-255.
367. Boke O., Gunes S., Kara N., et al. Association of serotonin 2A receptor and lack of association of CYP1A2 gene polymorphism with tardive dyskinesia in a Turkish population. DNA Cell Biol 2007, 26:527-531.
368. Bozina N., Medved V., Kuzman M.R., et al. Association study of olanzapine-induced weight gain and therapeutic response with SERT gene polymorphisms in female schizophrenic patients. J Psychopharmacol 2007, 21:728-734.
369. Chagnon Y.C., Bureau A., Gendron D., et al. Possible association of the pro-melanin-concentrating hormone gene with a greater body mass index as a side effect of the antipsychotic olanzapine. Am J Med Genet B Neuropsychiatr Genet 2007, 144B:1063-1069.
370. De L.V., Muller D.J., Hwang R., et al. HTR2C haplotypes and antipsychotics-induced weight gain: X-linked multimarker analysis. Hum Psychopharmacol. 2007, 22:463-467.
371. Dettling M., Cascorbi I., Opgen-Rhein C., et al. Clozapine-induced agranulocytosis in schizophrenic caucasians: confirming clues for associations with human leukocyte class I and II antigens. Pharmacogenomics J 2007, 7:325-332.
372. Dolzan V., Plesnicar B.K., Serretti A., et al. Polymorphisms in dopamine receptor DRD1 and DRD2 genes and psychopathological and extrapyramidal symptoms in patients on long-term antipsychotic treatment. Am J Med Genet B Neuropsychiatr Genet 2007, 144B:809-815.
373. Ellingrod V.L., Bishop J.R., Moline J., et al. Leptin and leptin receptor gene polymorphisms and increases in body mass index (BMI) from olanzapine treatment in persons with schizophrenia. Psychopharmacol Bull 2007, 40:57-62.
374. Greenbaum L., Strous R.D., Kanyas K., et al. Association of the RGS2 gene with extrapyramidal symptoms induced by treatment with antipsychotic medication. Pharmacogenet Genomics 2007, 17:519-528.
375. Gunes A., Scordo M.G., Jaanson P., et al. Serotonin and dopamine receptor gene polymorphisms and the risk of extrapyramidal side effects in perphenazine-treated schizophrenic patients. Psychopharmacology (Berl) 2007, 190:479-484.
376. Hwang R., Shinkai T., De L.V., et al. Association study of four dopamine D1 receptor gene polymorphisms and clozapine treatment response. J Psychopharmacol 2007, 21:718-727.
377. Kato D., Kawanishi C., Kishida I., et al. Effects of CYP2D6 polymorphisms on neuroleptic malignant syndrome. Eur J Clin Pharmacol 2007, 63:991-996.
378. Lee H.J., Kang S.G., Paik J.W., et al. No evidence for an association between G protein beta3 subunit gene C825T polymorphism and tardive dyskinesia in schizophrenia. Hum Psychopharmacol 2007, 22:501-504.
379. Lee H.J., Kang S.G., Choi J.E., et al. No association between dopamine D4 receptor gene -521 C/T polymorphism and tardive dyskinesia in schizophrenia. Neuropsychobiology 2007, 55:47-51.
380. Liou Y.J., Wang Y.C., Chen J.Y., et al. Association analysis of polymorphisms in the N-methyl-D-aspartate (NMDA) receptor subunit 2B (GRIN2B) gene and tardive dyskinesia in schizophrenia. Psychiatry Res 2007, 153:271-275.
381. Mancama D., Mata I., Kerwin R.W., et al. Choline acetyltransferase variants and their influence in schizophrenia and olanzapine response. Am J Med Genet B Neuropsychiatr Genet 2007, 144B:849-853.
382. Mo G.H., Lai I.C., Wang Y.C., et al. Support for an association of the C939T polymorphism in the human DRD2 gene with tardive dyskinesia in schizophrenia. Schizophr Res 2007, 97:302-304.
383. Molero P., Ortuno F., Zalacain M., et al. Clinical involvement of catechol-O-methyltransferase polymorphisms in schizophrenia spectrum disorders: influence on the severity of psychotic symptoms and on the response to neuroleptic treatment. Pharmacogenomics J 2007, 7:418-426.
384. Mulder H., Franke B., van der-Beek van der A.A., et al. The association between HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia. J Clin Psychopharmacol 2007, 27:338-343.
385. Mulder H., Franke B., van der-Beek van der A.A., et al. The association between HTR2C polymorphisms and obesity in psychiatric patients using antipsychotics: a cross-sectional study. Pharmacogenomics J 2007, 7:318-324.
386. Pae C.U., Kim T.S., Patkar A.A., et al. Manganese superoxide dismutase (MnSOD: Ala-9Val) gene polymorphism may not be associated with schizophrenia and tardive dyskinesia. Psychiatry Res 2007, 153:77-81.
387. Ryu S., Cho E.Y., Park T., et al. 759 C/T polymorphism of 5-HT2C receptor gene and early phase weight gain associated with antipsychotic drug treatment. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:673-677.
388. Tay J.K., Tan C.H., Chong S.A., et al. Functional polymorphisms of the cytochrome P450 1A2 (CYP1A2) gene and prolonged QTc interval in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:1297-1302.
389. Tiwari A.K., Deshpande S.N., Lerer B., et al. Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: V. Association of CYP1A2 1545 C>T polymorphism. Pharmacogenomics J 2007, 7:305-311.
390. Vijayan N.N., Bhaskaran S., Koshy L.V., et al. Association of dopamine receptor polymorphisms with schizophrenia and antipsychotic response in a South Indian population. Behav Brain Funct 2007, 3:34.
391. Wang L., Yu L., He G., et al. Response of risperidone treatment may be associated with polymorphisms of HTT gene in Chinese schizophrenia patients. Neurosci Lett 2007, 414:1-4.
392. Xing Q., Qian X., Li H., et al. The relationship between the therapeutic response to risperidone and the dopamine D2 receptor polymorphism in Chinese schizophrenia patients. Int J Neuropsychopharmacol 2007, 10:631-637.
393. Xu M.Q., Xing Q.H., Zheng Y.L., et al. Association of AKT1 gene polymorphisms with risk of schizophrenia and with response to antipsychotics in the Chinese population. J Clin Psychiatry 2007, 68:1358-1367.
394. Yue W., Kang G., Zhang Y., et al. Association of DAOA polymorphisms with schizophrenia and clinical symptoms or therapeutic effects. Neurosci Lett 2007, 416:96-100.
395. Zai C.C., Hwang R.W., De L.V., et al. Association study of tardive dyskinesia and twelve DRD2 polymorphisms in schizophrenia patients. Int J Neuropsychopharmacol 2007, 10:639-651.
396. Zhang A., Xing Q., Wang L., et al. Dopamine transporter polymorphisms and risperidone response in Chinese schizophrenia patients: an association study. Pharmacogenomics 2007, 8:1337-1345.
397. Zhang X.Y., Tan Y.L., Zhou D.F., et al. Association of clozapine-induced weight gain with a polymorphism in the leptin promoter region in patients with chronic schizophrenia in a Chinese population. J Clin Psychopharmacol 2007, 27:246-251.
398. Grossman I., Sullivan P.F., Walley N., et al. Genetic determinants of variable metabolism have little impact on the clinical use of leading antipsychotics in the CATIE study. Genet Med 2008, 10:720-729.
399. Bozina N., Kuzman M.R., Medved V., et al. Associations between MDR1 gene polymorphisms and schizophrenia and therapeutic response to olanzapine in female schizophrenic patients. J Psychiatr Res 2008, 42:89-97.
400. Adams D.H., Close S., Farmen M., et al. Dopamine receptor D3 genotype association with greater acute positive symptom remission with olanzapine therapy in predominately caucasian patients with chronic schizophrenia or schizoaffective disorder. Hum Psychopharmacol 2008, 23:267-274.
401. Al Hadithy A.F., Wilffert B., Stewart R.E., et al. Pharmacogenetics of parkinsonism, rigidity, rest tremor, and bradykinesia in African-Caribbean inpatients: differences in association with dopamine and serotonin receptors. Am J Med Genet B Neuropsychiatr Genet 2008, 147B:890-897.
402. Benmessaoud D., Hamdani N., Boni C., et al. Excess of transmission of the G allele of the -1438A/G polymorphism of the 5-HT2A receptor gene in patients with schizophrenia responsive to antipsychotics. BMC Psychiatry 2008, 8:40.
403. Campbell D.B., Ebert P.J., Skelly T., et al. Ethnic stratification of the association of RGS4 variants with antipsychotic treatment response in schizophrenia. Biol Psychiatry 2008, 63:32-41.
404. *6 polymorphisms and antipsychotic-induced extrapyramidal side-effects in patients receiving antipsychotic therapy. Clin Exp Pharmacol Physiol 2008, 35:807-811.
405. de L.J., Correa J.C., Ruano G., et al. Exploring genetic variations that may be associated with the direct effects of some antipsychotics on lipid levels. Schizophr Res 2008, 98:40-46.
406. Dolzan V., Serretti A., Mandelli L., et al. Acute antipyschotic efficacy and side effects in schizophrenia: association with serotonin transporter promoter genotypes. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:1562-1566.
407. Ellingrod V.L., Miller D.D., Taylor S.F., et al. Metabolic syndrome and insulin resistance in schizophrenia patients receiving antipsychotics genotyped for the methylenetetrahydrofolate reductase (MTHFR) 677C/T and 1298A/C variants. Schizophr Res 2008, 98:47-54.
408. Gu B., Wang L., Zhang A.P., et al. Association between a polymorphism of the HTR3A gene and therapeutic response to risperidone treatment in drug-naive Chinese schizophrenia patients. Pharmacogenet Genomics 2008, 18:721-727.
409. Gunes A., Dahl M.L., Spina E., et al. Further evidence for the association between 5-HT2C receptor gene polymorphisms and extrapyramidal side effects in male schizophrenic patients. Eur J Clin Pharmacol 2008, 64:477-482.
410. Hamdani N., Tabeze J.P., Ramoz N., et al. The CNR1 gene as a pharmacogenetic factor for antipsychotics rather than a susceptibility gene for schizophrenia. Eur Neuropsychopharmacol 2008, 18:34-40.
411. Ikeda M., Yamanouchi Y., Kinoshita Y., et al. Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia. Pharmacogenomics 2008, 9:1437-1443.
412. Ji X., Takahashi N., Branko A., et al. An association between serotonin receptor 3B gene (HTR3B) and treatment-resistant schizophrenia (TRS) in a Japanese population. Nagoya J Med Sci 2008, 70:11-17.
413. Ji X., Takahashi N., Saito S., et al. Relationship between three serotonin receptor subtypes (HTR3A, HTR2A and HTR4) and treatment-resistant schizophrenia in the Japanese population. Neurosci Lett 2008, 435:95-98.
414. Kang S.G., Choi J.E., An H., et al. Manganese superoxide dismutase gene Ala-9Val polymorphism might be related to the severity of abnormal involuntary movements in Korean schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:1844-1847.
415. Kang S.G., Choi J.E., An H., et al. No association between the brain-derived neurotrophic factor gene Val66Met polymorphism and tardive dyskinesia in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:1545-1548.
416. Kang S.G., Lee H.J., Choi J.E., et al. Association study between antipsychotics-induced restless legs syndrome and polymorphisms of dopamine D1, D2, D3, and D4 receptor genes in schizophrenia. Neuropsychobiology 2008, 57:49-54.
417. Kang S.G., Lee H.J., Park Y.M., et al. Possible association between the -2548A/G polymorphism of the leptin gene and olanzapine-induced weight gain. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:160-163.
418. Kim B., Choi E.Y., Kim C.Y., et al. Could HTR2A T102C and DRD3 Ser9Gly predict clinical improvement in patients with acutely exacerbated schizophrenia? Results from treatment responses to risperidone in a naturalistic setting. Hum Psychopharmacol 2008, 23:61-67.
419. Kohlrausch F.B., Salatino-Oliveira A., Gama C.S., et al. G-protein gene 825C>T polymorphism is associated with response to clozapine in Brazilian schizophrenics. Pharmacogenomics 2008, 9:1429-1436.
420. Kohlrausch F.B., Gama C.S., Lobato M.I., et al. Naturalistic pharmacogenetic study of treatment resistance to typical neuroleptics in European-Brazilian schizophrenics. Pharmacogenet Genomics 2008, 18:599-609.
421. Kwon J.S., Kim E., Kang D.H., et al. Taq1A polymorphism in the dopamine D2 receptor gene as a predictor of clinical response to aripiprazole. Eur Neuropsychopharmacol 2008, 18:897-907.
422. Lafuente A., Bernardo M., Mas S., et al. Polymorphism of dopamine D2 receptor (TaqIA, TaqIB, and-141C Ins/Del) and dopamine degradation enzyme (COMT G158A, A-278G) genes and extrapyramidal symptoms in patients with schizophrenia and bipolar disorders. Psychiatry Res 2008, 161:131-141.
423. Lane H.Y., Liu Y.C., Huang C.L., et al. RGS4 polymorphisms predict clinical manifestations and responses to risperidone treatment in patients with schizophrenia. J Clin Psychopharmacol 2008, 28:64-68.
424. Lavedan C., Volpi S., Polymeropoulos M.H., et al. Effect of a ciliary neurotrophic factor polymorphism on schizophrenia symptom improvement in an iloperidone clinical trial. Pharmacogenomics 2008, 9:289-301.
425. Liou Y.J., Wang Y.C., Chen J.Y., et al. The coding-synonymous polymorphism rs1045280 (Ser280Ser) in beta-arrestin 2 (ARRB2) gene is associated with tardive dyskinesia in Chinese patients with schizophrenia. Eur J Neurol 2008, 15:1406-1408.
426. Meary A., Brousse G., Jamain S., et al. Pharmacogenetic study of atypical antipsychotic drug response: involvement of the norepinephrine transporter gene. Am J Med Genet B Neuropsychiatr Genet 2008, 147B:491-494.
427. Mou X.D., Zhang Z.J., Zhang X.R., et al. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2008, 33:316-320. [in Chinese].
428. Pae C.U., Drago A., Kim J.J., et al. TAAR6 variation effect on clinic presentation and outcome in a sample of schizophrenic in-patients: an open label study. Eur Psychiatry 2008, 23:390-395.
429. Park Y.M., Cho J.H., Kang S.G., et al. Lack of association between the -759C/T polymorphism of the 5-HT2C receptor gene and olanzapine-induced weight gain among Korean schizophrenic patients. J Clin Pharm Ther 2008, 33:55-60.
430. Shao P., Zhao J.P., Chen J.D., et al. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2008, 33:312-315. [in Chinese].
431. Shinkai T., De L.V., Utsunomiya K., et al. Functional polymorphism of the human multidrug resistance gene (MDR1) and polydipsia-hyponatremia in schizophrenia. Neuromolecular Med 2008, 10:362-367.
432. Smith R.C., Segman R.H., Golcer-Dubner T., et al. Allelic variation in ApoC3, ApoA5 and LPL genes and first and second generation antipsychotic effects on serum lipids in patients with schizophrenia. Pharmacogenomics J 2008, 8:228-236.
433. Souza R.P., Romano-Silva M.A., Lieberman J.A., et al. Association study of GSK3 gene polymorphisms with schizophrenia and clozapine response. Psychopharmacology (Berl) 2008, 200:177-186.
434. Spellmann I., Muller N., Musil R., et al. Associations of SNAP-25 polymorphisms with cognitive dysfunctions in caucasian patients with schizophrenia during a brief trail of treatment with atypical antipsychotics. Eur Arch Psychiatry Clin Neurosci 2008, 258:335-344.
435. Srivastava V., Deshpande S.N., Nimgaonkar V.L., et al. Genetic correlates of olanzapine-induced weight gain in schizophrenia subjects from north India: role of metabolic pathway genes. Pharmacogenomics 2008, 9:1055-1068.
436. Wang L., Fang C., Zhang A., et al. The -1019 C/G polymorphism of the 5-HT(1)A receptor gene is associated with negative symptom response to risperidone treatment in schizophrenia patients. J Psychopharmacol 2008, 22:904-909.
437. Webb B.T., Sullivan P.F., Skelly T., et al. Model-based gene selection shows engrailed 1 is associated with antipsychotic response. Pharmacogenet Genomics 2008, 18:751-759.
438. Xu M.Q., St C.D., Feng G.Y., et al. BDNF gene is a genetic risk factor for schizophrenia and is related to the chlorpromazine-induced extrapyramidal syndrome in the Chinese population. Pharmacogenet Genomics 2008, 18:449-457.
439. Xuan J., Zhao X., He G., et al. Effects of the dopamine D3 receptor (DRD3) gene polymorphisms on risperidone response: a pharmacogenetic study. Neuropsychopharmacology 2008, 33:305-311.
440. Zai C.C., Romano-Silva M.A., Hwang R., et al. Genetic study of eight AKT1 gene polymorphisms and their interaction with DRD2 gene polymorphisms in tardive dyskinesia. Schizophr Res 2008, 106:248-252.
441. Need A.C., Keefe R.S., Ge D., et al. Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis. Eur J Hum Genet 2009, 17:946-957.
442. Tsai H.T., Caroff S.N., Miller D.D., et al. A candidate gene study of tardive dyskinesia in the CATIE schizophrenia trial. Am J Med Genet B Neuropsychiatr Genet 2010, 153B:336-340.
443. Al Hadithy A.F., Ivanova S.A., Pechlivanoglou P., et al. Tardive dyskinesia and DRD3, HTR2A and HTR2C gene polymorphisms in Russian psychiatric inpatients from Siberia. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:475-481.
444. Al Hadithy A.F., Wilffert B., Bruggeman R., et al. Lack of association between antipsychotic-induced Parkinsonism or its subsymptoms and rs4606 SNP of RGS2 gene in African-Caribbeans and the possible role of the medication: the Curacao extrapyramidal syndromes study X. Hum Psychopharmacol 2009, 24:123-128.
445. Angelucci F., Bernardini S., Gravina P., et al. Delusion symptoms and response to antipsychotic treatment are associated with the 5-HT2A receptor polymorphism (102T/C) in Alzheimer's disease: a 3-year follow-up longitudinal study. J Alzheimers Dis 2009, 17:203-211.
446. Barlas I.O., Cetin M., Erdal M.E., et al. Lack of association between DRD3 gene polymorphism and response to clozapine in Turkish schizoprenia patients. Am J Med Genet B Neuropsychiatr Genet 2009, 150B:56-60.
447. Calarge C.A., Ellingrod V.L., Zimmerman B., et al. Leptin gene -2548G/A variants predict risperidone-associated weight gain in children and adolescents. Psychiatr Genet 2009, 19:320-327.
448. Chen S.F., Shen Y.C., Chen C.H. HTR2A A-1438G/T102C polymorphisms predict negative symptoms performance upon aripiprazole treatment in schizophrenic patients. Psychopharmacology (Berl) 2009, 205:285-292.
449. Chen S.F., Shen Y.C., Chen C.H. Effects of the DRD3 Ser9Gly polymorphism on aripiprazole efficacy in schizophrenic patients as modified by clinical factors. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:470-474.
450. Consoli G., Lastella M., Ciapparelli A., et al. ABCB1 polymorphisms are associated with clozapine plasma levels in psychotic patients. Pharmacogenomics 2009, 10:1267-1276.
451. Du J., Zhang A., Wang L., et al. Relationship between response to risperidone, plasma concentrations of risperidone and CYP3A4 polymorphisms in schizophrenia patients. J Psychopharmacol 2010, 24(7):1115-1120.
452. Gasso P., Mas S., Bernardo M., et al. A common variant in DRD3 gene is associated with risperidone-induced extrapyramidal symptoms. Pharmacogenomics J 2009, 9:404-410.
453. Godlewska B.R., Olajossy-Hilkesberger L., Ciwoniuk M., et al. Olanzapine-induced weight gain is associated with the -759C/T and -697G/C polymorphisms of the HTR2C gene. Pharmacogenomics J 2009, 9:234-241.
454. Greenbaum L., Smith R.C., Rigbi A., et al. Further evidence for association of the RGS2 gene with antipsychotic-induced parkinsonism: protective role of a functional polymorphism in the 3'-untranslated region. Pharmacogenomics J 2009, 9:103-110.
455. Gregoor J.G., van der Weide J., Mulder H., et al. Polymorphisms of the LEP- and LEPR gene and obesity in patients using antipsychotic medication. J Clin Psychopharmacol 2009, 29:21-25.
456. Gunes A., Melkersson K.I., Scordo M.G., et al. Association between HTR2C and HTR2A polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine. J Clin Psychopharmacol 2009, 29:65-68.
457. Gupta M., Bhatnagar P., Grover S., et al. Association studies of catechol-O-methyltransferase (COMT) gene with schizophrenia and response to antipsychotic treatment. Pharmacogenomics 2009, 10:385-397.
458. Herken H., Erdal M., Aydin N., et al. The association of olanzapine-induced weight gain with peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism in patients with schizophrenia. DNA Cell Biol 2009, 28:515-519.
459. Jaquenoud S.E., Knezevic B., Morena G.P., et al. ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine. J Clin Psychopharmacol 2009, 29:319-326.
460. Kang S.G., Lee H.J., Choi J.E., et al. Association study between glutathione S-transferase GST-M1, GST-T1, and GST-P1 polymorphisms and tardive dyskinesia. Hum Psychopharmacol 2009, 24:55-60.
461. Kobylecki C.J., Jakobsen K.D., Hansen T., et al. CYP2D6 genotype predicts antipsychotic side effects in schizophrenia inpatients: a retrospective matched case-control study. Neuropsychobiology 2009, 59:222-226.
462. Kwon J.S., Joo Y.H., Nam H.J., et al. Association of the glutamate transporter gene SLC1A1 with atypical antipsychotics-induced obsessive-compulsive symptoms. Arch Gen Psychiatry 2009, 66:1233-1241.
463. *1F and serotonergic polymorphisms influence therapeutic outcome. Pharmacogenomics J 2010, 10(1):20-29.
464. Le H.S., Theisen F.M., Haberhausen M., et al. Association between the insulin-induced gene 2 (INSIG2) and weight gain in a German sample of antipsychotic-treated schizophrenic patients: perturbation of SREBP-controlled lipogenesis in drug-related metabolic adverse effects?. Mol Psychiatry 2009, 14:308-317.
465. Lee H.Y., Kim D.J., Lee H.J., et al. No association of serotonin transporter polymorphism (5-HTTVNTR and 5-HTTLPR) with characteristics and treatment response to atypical antipsychotic agents in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:276-280.
466. Liou Y.J., Chen M.L., Wang Y.C., et al. Analysis of genetic variations in the RGS9 gene and antipsychotic-induced tardive dyskinesia in schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2009, 150B:239-242.
467. Mossner R., Schuhmacher A., Kuhn K.U., et al. Functional serotonin 1A receptor variant influences treatment response to atypical antipsychotics in schizophrenia. Pharmacogenet Genomics 2009, 19:91-94.
468. Mulder H., Cohen D., Scheffer H., et al. HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia: a replication study. J Clin Psychopharmacol 2009, 29:16-20.
469. Park S.W., Lee J.G., Kong B.G., et al. Genetic association of BDNF val66met and GSK-3beta-50T/C polymorphisms with tardive dyskinesia. Psychiatry Clin Neurosci 2009, 63:433-439.
470. Sickert L., Muller D.J., Tiwari A.K., et al. Association of the alpha2A adrenergic receptor -1291C/G polymorphism and antipsychotic-induced weight gain in European-Americans. Pharmacogenomics 2009, 10:1169-1176.
471. Volpi S., Potkin S.G., Malhotra A.K., et al. Applicability of a genetic signature for enhanced iloperidone efficacy in the treatment of schizophrenia. J Clin Psychiatry 2009, 70:801-809.
472. Wei Z., Wang L., Xuan J., et al. Association analysis of serotonin receptor 7 gene (HTR7) and risperidone response in Chinese schizophrenia patients. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:547-551.
473. Wilffert B., Al Hadithy A.F., Sing V.J., et al. The role of dopamine D3, 5-HT2A and 5-HT2C receptor variants as pharmacogenetic determinants in tardive dyskinesia in African-Caribbean patients under chronic antipsychotic treatment: curacao extrapyramidal syndromes study IX. J Psychopharmacol 2009, 23:652-659.
474. Zai C.C., Tiwari A.K., Basile V., et al. Association study of tardive dyskinesia and five DRD4 polymorphisms in schizophrenia patients. Pharmacogenomics J 2009, 9:168-174.
475. Zai C.C., Tiwari A.K., Basile V., et al. Oxidative stress in tardive dyskinesia: genetic association study and meta-analysis of NADPH quinine oxidoreductase 1 (NQO1) and Superoxide dismutase 2 (SOD2, MnSOD) genes. Prog Neuropsychopharmacol Biol Psychiatry 2009, 114(1-3):33-38.
476. Zuo L., Luo X., Krystal J.H., et al. The efficacies of clozapine and haloperidol in refractory schizophrenia are related to DTNBP1 variation. Pharmacogenet Genomics 2009, 19:437-446.
477. McClay J.L., Adkins D.E., Aberg K., et al. Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics. Mol Psychiatry 2009, [Epub ahead of print].
478. Alkelai A., Greenbaum L., Rigbi A., et al. Genome-wide association study of antipsychotic-induced parkinsonism severity among schizophrenia patients. Psychopharmacology (Berl) 2009, 206:491-499.
479. Aberg K., Adkins D.E., Bukszar J., et al. Genome-wide association study of movement-related adverse antipsychotic effects. Biol Psychiatry 2010, 67(3):279-282.
480. Lavedan C., Licamele L., Volpi S., et al. Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study. Mol Psychiatry 2009, 14:804-819.
481. Volpi S., Heaton C., Mack K., et al. Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia. Mol Psychiatry 2009, 14:1024-1031.
482. Arranz M.J., de L.J. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol Psychiatry 2007, 12:707-747.
483. Patsopoulos N.A., Ntzani E.E., Zintzaras E., et al. CYP2D6 polymorphisms and the risk of tardive dyskinesia in schizophrenia: a meta-analysis. Pharmacogenet Genomics 2005, 15:151-158.
484. Miyamoto S., Duncan G.E., Marx C.E., et al. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 2005, 10:79-104.
485. Lieberman J.A. Dopamine partial agonists: a new class of antipsychotic. CNS Drugs 2004, 18:251-267.
486. Mamo D., Kapur S., Shammi C.M., et al. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am J Psychiatry 2004, 161:818-825.
487. Arinami T., Gao M., Hamaguchi H., et al. A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. Hum Mol Genet 1997, 6:577-582.
488. Jonsson E.G., Nothen M.M., Grunhage F., et al. Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol Psychiatry 1999, 4:290-296.
489. Goldman D., Urbanek M., Guenther D., et al. A functionally deficient DRD2 variant [Ser311Cys] is not linked to alcoholism and substance abuse. Alcohol 1998, 16:47-52.
490. Bakker P.R., van Harten P.N., van O.J. Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions. Mol Psychiatry 2008, 13:544-556.
491. Lundstrom K., Turpin M.P. Proposed schizophrenia-related gene polymorphism: expression of the Ser9Gly mutant human dopamine D3 receptor with the Semliki forest virus system. Biochem Biophys Res Commun 1996, 225:1068-1072.
492. Bakker P.R., van Harten P.N., van O.J. Antipsychotic-induced tardive dyskinesia and the Ser9Gly polymorphism in the DRD3 gene: a meta analysis. Schizophr Res 2006, 83:185-192.
493. Meltzer H.Y. Role of serotonin in the action of atypical antipsychotic drugs. Clin Neurosci 1995, 3:64-75.
494. Meltzer H.Y., Li Z., Kaneda Y., et al. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2003, 27:1159-1172.
495. Kroeze W.K., Kristiansen K., Roth B.L. Molecular biology of serotonin receptors structure and function at the molecular level. Curr Top Med Chem 2002, 2:507-528.
496. Arranz M.J., Munro J., Sham P., et al. Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response. Schizophr Res 1998, 32:93-99.
497. Lerer B., Segman R.H., Tan E.C., et al. Combined analysis of 635 patients confirms an age-related association of the serotonin 2A receptor gene with tardive dyskinesia and specificity for the non-orofacial subtype. Int J Neuropsychopharmacol 2005, 8:411-425.
498. De L.V., Mueller D.J., de B.A., et al. Association of the HTR2C gene and antipsychotic induced weight gain: a meta-analysis. Int J Neuropsychopharmacol 2007, 10:697-704.
499. Roche Molecular systems I. AmpliChip CYP450 test for in vitro diagnostic use. Roche Diagnostics 2006, [Epub ahead of print].
500. Katsanis S.H., Javitt G., Hudson K. Public health: a case study of personalized medicine. Science 2008, 320:53-54.
501. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group Recommendations from the EGAPP Working Group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors. Genet Med 2007, 9:819-825.
502. Wagner J.A. Overview of biomarkers and surrogate endpoints in drug development. Dis Markers 2002, 18:41-46.
503. FDA Guidance for industry: pharmacogenomic data submission. FDA 2005.
504. Frueh F.W., Amur S., Mummaneni P., et al. Pharmacogenomic biomarker information in drug labels approved by the United States Food and Drug Administration: prevalence of related drug use. Pharmacotherapy 2008, 28:992-998.
505. Arranz M.J., Kapur S. Pharmacogenetics in psychiatry: are we ready for widespread clinical use?. Schizophr Bull 2008, 34:1130-1144.
506. van der W.J., Steijns L.S., van Weelden M.J. The effect of smoking and cytochrome P450 CYP1A2 genetic polymorphism on clozapine clearance and dose requirement. Pharmacogenetics 2003, 13:169-172.
507. Desai H.D., Seabolt J., Jann M.W. Smoking in patients receiving psychotropic medications: a pharmacokinetic perspective. CNS Drugs 2001, 15:469-494.
508. Spina E., de L.J. Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol 2007, 100:4-22.